



Universiteit
Leiden
The Netherlands

Navigating solute carrier transporters: a comprehensive review of functionalized small molecule probes for target identification and characterization

Dilweg, M.A.; Widjaja, T.; IJzerman, A.P.; Es, D. van der

Citation

Dilweg, M. A., Widjaja, T., IJzerman, A. P., & Es, D. van der. (2026). Navigating solute carrier transporters: a comprehensive review of functionalized small molecule probes for target identification and characterization. *Medicinal Research Reviews*, 46(1), 238-271. doi:10.1002/med.70009

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from: <https://hdl.handle.net/1887/4285598>

Note: To cite this publication please use the final published version (if applicable).

REVIEW ARTICLE OPEN ACCESS

Navigating Solute Carrier Transporters—A Comprehensive Review of Functionalized Small Molecule Probes for Target Identification and Characterization

Majlen A. Dilweg  | Tracie Widjaja | Adriaan P. IJzerman  | Daan van der Es 

Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands

Correspondence: Daan van der Es (d.van.der.es@lacdr.leidenuniv.nl)

Received: 25 November 2024 | **Revised:** 23 May 2025 | **Accepted:** 13 August 2025

Keywords: chemical biology | chemical probes | drug discovery | small molecules | solute carrier transporters

ABSTRACT

Solute carrier transporters (SLCs) are integral membrane proteins that play pivotal roles in maintaining cellular homeostasis by mediating the transport of a diverse range of substrates across cell membranes. With their involvement in fundamental physiological processes such as nutrient uptake, neurotransmitter signaling, and drug transport, SLCs have emerged as crucial players in health and disease. Dysregulation of SLC function has been implicated in a spectrum of disorders, including metabolic diseases, cancer, and neurological afflictions. Despite their significance, SLCs remain relatively understudied compared to other protein classes, resulting in a gap in understanding their molecular mechanisms of action and potential as therapeutic targets. This review aims to address this gap by providing a comprehensive overview of the diverse array of small-molecule probes utilized in the study of SLCs. Various types of functionalized probes, amongst which fluorescent probes, bivalent probes, covalent inhibitors, affinity-based probes, photoswitchable inhibitors and proteolysis targeting chimeras (PROTACs), have been designed to investigate transporter function, substrate specificity, and regulatory mechanisms. In this review, we describe the principles underlying the design and synthesis of these probes, highlights key examples of their application in elucidating transporter function and regulation, and discuss insights gained from such studies. Furthermore, we examine current challenges and future directions in the development and utilization of small-molecule probes for SLC transporter research. By shedding light on the intricate mechanisms involved in transporter

Abbreviations: 2-NBDG, 2-[N-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)-amino]-2-deoxyglucose; 5-HT, 5-hydroxytryptamine (serotonin); AAC1, ADP/ATP carrier (old nomenclature ANT1); ABC, ATP-binding cassette; ABP, activity-based probe; ADME, absorption, distribution, metabolism, and excretion; ADP, adenosine diphosphate; AE1, anion exchanger 1; AFBP, affinity-based probe; ANT1, mitochondrial adenine nucleotide translocator 1; AOG, (2'-azi-*n*-octanol)- β -*D*-glucoside; APP⁺, 4-(4-(dimethylamino)phenyl)-1-methylpyridin-1-ium; ASBT, apical sodium ion-dependent bile acid transporter; ASCT2, alanine/serine/cysteine transporter 2; ATP, adenosine triphosphate; BODIPY, boron-dipyrromethene; BPP⁺, 1-butyl-4-(4-(dimethylamino)phenyl)pyridin-1-ium; BzG, [(4'-benzoyl)phenyl]-*D*-glucopyranoside; CCC9, cation-chloride cotransporter 9; CDCA, chenodeoxycholic acid; CNT, concentrative nucleoside transporter; CTL4, choline transporter-like 4; CuAAC, copper(I)-catalyzed azide-alkyne cycloaddition; Cy, cyanine; DAT, dopamine transporter; DBD, 4-*N,N*-dimethylaminosulfonyl-2,1,3-benzoxadiazole; DCPO, (E)-2-(2-(4-hydroxystyryl)-4H-chromen-4-ylidene)-malononitrile; DCSN, (E)-2-(3-(4-(diethylamino)styryl)-5,5-dimethylcyclohex-2-en-1-ylidene)malononitrile; dSTORM, direct stochastic optical reconstruction microscopy; dTAG, degradation tag; EAAT, excitatory amino acid transporter; ECHD, epoxycyclohexenedione; EMA, European Medicines Agency; ER, endoplasmic reticulum; FATP3, fatty acid transport protein 3; FDA, U.S. Food and Drug Administration; FFF, fully functionalized fragment; FFN, fluorescent false neurotransmitter; FITC, fluorescein isothiocyanate; FRET, Förster (or fluorescence) resonance energy transfer; GABA, γ -aminobutyric acid; GAT, γ -aminobutyric acid transporter; GDC, Graves disease carrier; Glt_{TK}, glutamate transporter (*Thermococcus kodakarensis*); GLUT, glucose transporter; GlyT, glycine transporter; GOLD, gating-oriented live-cell distinction; GPCR, G protein-coupled receptor; IFN, interferon; IngMeb, Ingenol mebutate; LAT1, L-type amino acid transporter 1; LYTAG, lysosome targeting chimeras; MAT, monoamine transporter; MATE, multidrug and toxin extrusion protein; MCT, monocarboxylate transporter; MPC2, mitochondrial pyruvate carrier subunit 2; MS, mass spectrometry; mTOR, mammalian target of rapamycin; NBD-MTMA, *N,N,N*-trimethyl-2-(methyl(7-nitrobenzof[c][1,2,5]oxadiazol-4-yl)amino)ethan-1-aminium; NBD-TMA, *N,N,N*-trimethyl-2-(7-nitrobenzof[c][1,2,5]oxadiazol-4-yl)amino)ethan-1-aminium; NETI, *S*-(4-nitrobenzyl)-6-thioinosine; NET, norepinephrine transporter; NHE1, sodium-hydrogen antiporter 1; NIR, near-infrared; NPC, Niemann-Pick disease type C; NPC1, NPC intracellular cholesterol transporter 1; NT, nucleoside transporter; NTCP, sodium/bile acid and sulphated solute cotransporter 1; OAT, organic anion transporter; OATP, organic anion transporting polypeptide; OCT, organic cation transporter; PARADISO, paralog-dependent isogenic cell assay; PAT1, proton-coupled amino acid transporter 1; PHT1, peptide transporter 4; POI, protein of interest; PPP⁺, 1-methyl-4-(4-(piperidin-1-yl)phenyl)pyridin-1-ium; PROTAC, proteolysis targeting chimeras; ROS, reactive oxygen species; SAEATA, 5'-*S*-(2-aminoethyl)-*N*⁶-(4-azidobenzyl)-5'-thioadenosine; SAENTA, 5'-*S*-(2-aminoethyl)-*N*⁶-(4-nitrobenzyl)-5'-thioadenosine; SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; SERT, serotonin transporter; SGLT, sodium-glucose cotransporter; SLC, solute carrier transporter; TCA, taurocholic acid; TCI, targeted covalent inhibitor; TFB-TBOA, TFB-threo- β -benzyloxypartate acid; THCA, 3 α ,7 α ,12 α -trihydroxy-5 β -cholestan-26-oic acid; TIPDG, [2'-iodo-4'-(3'-trifluoromethylidiaziryl)phenoxy]-*D*-glucopyranoside; TPD, targeted protein degradation; T-ALL, T cell acute lymphoblastic leukemia; VMAT, vesicular monoamine transporter; ZIP7, zinc transporter 7; ZmYS1, iron-phytosiderophore/yellow stripe 1 transporter (*Zea mays*); ZnT3, zinc transporter 3.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2025 The Author(s). *Medicinal Research Reviews* published by Wiley Periodicals LLC.

function and regulation, this review not only enhances the understanding of SLCs but also highlights their potential as therapeutic targets in drug discovery and thereby may facilitate systematic implementation of these innovative research approaches and the refinement of existing methodologies.

1 | Introduction

Cellular processes rely on complex mechanisms that ensure the proper transport of essential molecules across the cell membranes. Among these mechanisms, solute carrier transporters (SLCs) stand out as fundamental players in maintaining cellular homeostasis and facilitating multiple physiological functions [1]. With over 455 members organized into 66 subfamilies, SLCs form a diverse protein family, second in abundance only to G protein-coupled receptors (GPCRs) [2, 3]. These membrane-bound proteins mediate the translocation of a broad range of substrates, including ions, nutrients, neurotransmitters, and metabolites, across the cell as well as organelle membranes [4, 5]. While SLCs exhibit a general consistency in the types of molecules they transport within their subfamilies, individual proteins can display varying degrees of selectivity. Some SLCs transport a range of biomolecules, while others are restricted to a single type, and some remain “orphan” transporters with no known substrate [1, 6, 7]. Moreover, while SLCs encompass a wide spectrum of transport activities within various cell organelles, the majority of the identified transporters are known for their presence at the cell surface, specifically on the plasma membrane [4]. SLCs operate through facilitative transport where substrates move down their concentration gradients, or secondary active transport, in which the movement of one solute down its gradient provides energy for the transport of another solute against its respective gradient [5]. Within the latter, SLCs can function as symporters or antiporters, dynamically mediating the simultaneous or opposite movement of multiple solutes across membranes.

The transport function of SLCs, acting as the primary regulator of molecules entering and leaving cells, is intricately linked to a wide range of cellular and physiological processes. Certain SLC families control essential nutrient transport across membranes, impacting metabolism, energy production, and biosynthesis [8]. SLCs are also involved in the efflux of metabolic waste products from cells, facilitating detoxification while maintaining cellular homeostasis [4]. In addition, SLCs are integral components of the neurotransmitter system, modulating the synaptic concentrations of neurotransmitters and their precursors by means of neurotransmitter transporters such as norepinephrine transporter (NET, SLC6A2), dopamine transporter (DAT, SLC6A3), serotonin transporter (SERT, SLC6A4), and γ -aminobutyric acid transporters (GATs, SLC6 family) [9].

SLCs are also known to influence drug pharmacokinetics and pharmacodynamics, whether it is through direct or indirect mechanisms [10–12]. Drug transporters like the organic cation and anion transporters (OCTs, OATs respectively, SLC22 family), nucleoside transporters (NTs, SLC28 and SLC29 families), and multidrug and toxin extrusion proteins (MATEs, SLC47 family) facilitate the bidirectional transport of a wide array of drugs across the biological membranes in important ADME-related organs such as intestine, liver and kidney [11, 13, 14]. Upregulation or

inhibition of these transporters can lead to drug-drug interactions when multiple drugs compete for the same transporter, altering therapeutic efficacy and toxicity [10, 15]. Emphasizing the crucial role of SLC proteins in drug absorption across various interfaces, recent FDA and EMA guidelines even highlight the importance of screening these proteins for potential drug-drug interactions, with analyses linking numerous pharmacological compounds to transporter activity [16, 17].

As a consequence of the significant roles that SLCs play, dysfunction of SLCs has been linked to a spectrum of pathophysiological conditions. Polymorphisms in SLC genes have been connected to complex disorders [18]. For instance, mutations in genes encoding SLCs, such as with monocarboxylate transporter 1 (MCT1, SLC16A1) and zinc transporter 3 (ZnT3, SLC30A3), can lead to inherited metabolic disorders characterized by impaired nutrient absorption or excretion [19]. Moreover, alterations in the expression or activity of SLCs, such as cation-chloride cotransporter 9 (CCC9, SLC12A8) and choline transporter-like 4 (CTL4, SLC44A4), have been implicated in the development and progression of various cancers [20, 21]. Dysregulated nutrient transport mediated by SLCs can contribute to the metabolic reprogramming observed in cancer cells, supporting their proliferation and survival [22–24]. Additionally, irregular expression of drug transporters can result in multidrug resistance in cancer cells, limiting the efficacy of chemotherapy and leading to treatment failure [25].

Despite their significance, SLCs remain significantly understudied when compared to other protein classes of similar importance, with a narrowed focus in drug discovery on specific members [26–28]. This bias does not consistently align with functional significance, with some owing their status to positive feedback loops from previous successes and experimental convenience, while other SLCs gained prominence due to their role as targets for existing drugs. Exploring the reasons behind this study gap also reveals a series of challenges, such as the lack of a universal classification system, difficulties in protein purification and crystallization, and limited availability of cell-based assays [29, 30]. Moreover, challenges in replicating physiological conditions in transport assays further hinder our ability to simultaneously explore the structural and functional aspects of human SLC proteins, highlighting the need for innovative approaches in SLC research. To overcome this, the RESOLUTE consortium aimed to advance research on solute carriers (SLCs) by systematically characterizing these transport proteins to unlock their potential as therapeutic targets [31, 32]. The public-private partnership, supported by the European Innovative Medicines Initiative, developed comprehensive tools and resources, such as in vitro assays and data sets, to enhance understanding and facilitate the discovery of novel drug targets within the SLC family [33].

Besides being studied from an assay perspective, multiple new chemical modulators for SLCs have been developed in this

regard [34]. These small molecules, which are designed to bind to and modulate the activity of specific transporters, provide a means to investigate transporter function, substrate specificity, and regulatory mechanisms both in vitro and in vivo [35]. By utilizing such chemical probes, it is not only possible to elucidate the physiological roles of individual SLCs, but also to uncover their involvement in disease processes, and identify potential therapeutic targets for drug development. Chemical probes provide flexibility by enabling studies in the native environment without extensive purification or crystallization of target proteins, thereby preserving natural conformation and function [36]. Besides the classical chemical probes, which have been reviewed previously, a range of more functionalized tool molecules emerged as an invaluable addition to the resources that are available to study SLCs. These functionalized probes are often equipped with detection or purification handles, while still being designed with high selectivity to target specific SLCs. Among other things, functionalized chemical probes can facilitate the observation of dynamic conformational changes in real-time, a challenge for static methods like crystallization or computational docking experiments.

While several comprehensive reviews of these tools are available for other protein families like GPCRs, a complete overview of what is available for SLCs is still missing [37–39]. Therefore, in this review, we aim to provide a comprehensive overview of the diverse array of small-molecule chemical probes employed

as tools in the study of SLCs. While the focus will primarily be on fluorescent probes, covalent inhibitors, affinity-based probes (AfBPs), bitopic probes such as bivalent ligands and proteolysis targeting chimeras (PROTACs), and photoswitchable probes (schematically represented in Figure 1), it is also important to note the existence of other chemical probes that are as important yet too extensive to cover. We have considered newly designed or synthesized probes from 2000 up until July 2024 to ensure relevance to current research, which have been summarized in Table 1 at the end of this review. We explore the principles underlying the design and synthesis of these probes, highlight key examples of their application in elucidating transporter function and regulation, and discuss the insights gained from such studies. Furthermore, we examine the current challenges and future directions in expanding the SLC toolbox and therefore the development and utilization of small molecule probes for SLC research.

2 | Fluorescent Probes

Small molecule fluorescent probes are essential tools in drug discovery, offering high sensitivity and versatility for studying protein localization, interactions, and dynamics [114, 115]. These probes, primarily organic dyes, have significantly advanced our understanding of protein behavior across various biological contexts. Compared to traditional functionalized probes such as




FIGURE 1 | Schematic representation of functionalized small molecule probes for SLCs discussed in this review. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

TABLE 1 | Overview of all functionalized small molecule probes and their target SLCs including their functionality, activity or affinity values discussed in this review.

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
Fluorescent probes (Figures 2 and 3)						
1	Glu-1N-Cy3	Substrate	n.r.	GLUTs	[132]	Includes Glu-1N-Cy5 in article
2	6N-Gly-Cy3	Substrate	n.r.	GLUTs	[133]	Includes 6N-Gly-Cy5 in article
3	Glu-Alexa532	Substrate	n.r.	GLUT1 (SLC2A1)	[134]	
4	N2	Substrate	n.r.	GLUT1 (SLC2A1)	[135, 136]	Includes other probes in article
5	ASqαGl	Substrate	n.r.	GLUTs	[40]	
6	Glc-SiR-CO ₂ H	Substrate	n.r.	GLUT1 (SLC2A1) GLUT4 (SLC2A4)	[41]	Includes version with another fluorophore in article
7	Glu-1-O-DCSN	Substrate	n.r.	GLUTs	[42]	
8	WZB117-IR820	Inhibitor	n.r.	GLUT1 (SLC2A1)	[43]	Includes a FITC version in article
9	PPP ⁺	Substrate	n.r.	SERT (SLC6A4)	[44]	
10	BPP ⁺	Substrate	n.r.	SERT (SLC6A4)	[44]	
11	MFN103	Substrate	n.r.	DAT (SLC6A3) VMAT2 (SLC18A2)	[45]	Earlier reported as Mini103 in SI of Lee et al. [46]
12	SERTlight	Substrate	K _T ~ 100 μM (apparent Michaelis-Menten constant)	SERT (SLC6A4)	[47]	
13	HT-CA	Substrate	n.r.	SERT (SLC6A4)	[48]	
14	PA-CA	Inhibitor	n.r.	SERT (SLC6A4)	[48]	
15	GC04-38	Inhibitor	K _i : 191 ± 16.5 nM	DAT (SLC6A3)	[49]	Highly selective; includes other fluorescent probes of same chemotype in article
16	ZWZ-3	Substrate	n.r.	OATP (SLCO)	[50]	
17	CDrB	Substrate	n.r.	OATP1B3 (SLCO1B3, influx) SCaMC-3L (SLC25A41, efflux)	[51]	
18	IR-817	Substrate	n.r.	OATP (SLCO)	[52]	

(Continues)

TABLE 1 | (Continued)

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
19	rose bengal	Substrate	n.r.	OATP1B1 (SLCO1B1) OATP1B3 (SLCO1B3)	[53]	
20	SAENTA-Cy5	Inhibitor	n.r.	ENT1 (SLC29A1)	[54]	
21	UCPH-102F	Inhibitor	pIC ₅₀ : 4.85 ± 0.05	EAAT1 (SLC1A3)	[55]	Due to unspecific binding could not be visualized with microscopy
22	6FGA	Substrate	K _m : 20.3 μM	SGLT (SLC5)	[56]	
23	10i/SC70-p	Inhibitor	pIC ₅₀ : 5.11 ± 0.05 (mGAT2) pIC ₅₀ : 5.15 ± 0.05 (mGAT4) pK _i : 6.40 ± 0.07 (GlyT2)	mGAT (Slc6) GlyT2 (SLC6A5)	[57, 58]	
24	tauro-nor-THCA-24-DBD	substrate	K _m : 40.6 ± 14.0 μM	ASBT (SLC10A2)	[59]	Previously reported for NTCP (SLC10A1) by de Bruyn <i>et al.</i> [60]
25	NBD-TMA	Substrate	n.r.	OCT2 (SLC22A2)	[61]	
26	NBD-MTMA	Substrate	n.r.	OCT2 (SLC22A2) MATE1 (SLC47A1)	[62]	
27	CDoB	Substrate	n.r.	GDC (SLC25A16)	[63]	
28	CDg18	Substrate	n.r.	FATP3 (SLC27A3)	[64]	
29	uridine-furan	Substrate	EC ₅₀ : 0.5 ± 0.1 μM (CNT1) EC ₅₀ : 1.6 ± 0.5 μM (CNT3)	CNT1 (SLC28A1) CNT3 (SLC28A3)	[65]	
30	fluorescent nicotianamine 15	Substrate	n.r.	PAT1 (SLC36A1)	[66]	
Photoreactive covalent inhibitors (Figure 4)						
31	Compound 4	Inhibitor	K _i : 60 μM	GLUT4 (SLC2A4)	[67]	Species: rat; includes other photo-AfBP of same chemotype in article
32	TIPDG	Inhibitor	K _i : 22 ± 5 μM	SGLT1 (SLC5A1)	[68]	Species: rabbit
33	BzG	Inhibitor	K _i : 12 ± 2 μM	SGLT1 (SLC5A1)	[68]	Species: rabbit; structure wrongly depicted in original article [68]
34	AOG	Inhibitor	K _i : 43 ± 12 μM	SGLT1 (SLC5A1)	[69]	Species: hog
35	Compound 15	Inhibitor	IC ₅₀ : 0.11 ± 0.02 μM (EAAT1)	EAAT1 (SLC1A3)	[70]	

(Continues)

TABLE 1 | (Continued)

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
36	Compound 16	Inhibitor	IC ₅₀ : 0.40 ± 0.03 μM (EAAT2) IC ₅₀ : 4.03 ± 0.80 μM (EAAT3)	EAAT2 (SLC1A2) EAAT3 (SLC1A1)	[70]	
Electrophilic covalent inhibitors (Figure 5)						
37	Compound 26	Inhibitor	IC ₅₀ : 31.5 ± 3.1 nM	DAT (SLC6A3)	[71]	Species: rat; includes other covalent inhibitors of same chemotype in article
38	Compound 16	Inhibitor	K _i : 537 ± 37 nM	DAT (SLC6A3)	[72]	Species: rat
39	Compound 14b	Inhibitor	IC ₅₀ : 68.3 ± 6.6 nM	DAT (SLC6A3)	[73]	Species: rat; includes other covalent inhibitors of same chemotype in article
40	HD-205	Inhibitor	IC ₅₀ : 284 ± 92 nM (NET) IC ₅₀ : 4.07 ± 0.93 nM (DAT) IC ₅₀ : 14.1 ± 0.91 nM (SERT)	NET (SLC6A2) DAT (SLC6A3) SERT (SLC6A4)	[74]	Species: rat; includes HD-244 as one-step AFBP in article
41	Compound 6	Inhibitor	IC ₅₀ : 24 nM	DAT (SLC6A3)	[75]	
42	1,2,3-dithiazoles	Inhibitors	—	LAT1 (SLC7A5) ASCT2 (SLC1A5)	[76, 159]	Includes multiple covalent inhibitors of same chemotype in article for both SLCs
43	1,2,4-dithiazines	Inhibitors	—	LAT1 (SLC7A5)	[159]	Includes multiple covalent inhibitors of same chemotype in article
44	3β-Cl-CDCA	Inhibitor	K _i : 0.81 μM	ASBT (SLC10A2)	[77]	
45	7α-Ms-CDCA	Inhibitor	K _i : 1.19 μM	ASBT (SLC10A2)	[77]	
46	TF2A	Inhibitor	Remaining [³ H]-TC uptake at 100 μM: 37.4 ± 2.8%	ASBT (SLC10A2)	[78]	
47	TF2B	Inhibitor	Remaining [³ H]-TC uptake at 100 μM: 33.8 ± 4.0%	ASBT (SLC10A2)	[78]	

(Continues)

TABLE 1 | (Continued)

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
48	AMM-59	Inhibitor	n.r.	ANT1 (SLC25A4)	[79]	Species: bovine; includes AMM-120 as two-step AfBP in article
49	YY4	Inhibitor	n.r.	MCP2 (SLC54A2)	[80]	Includes YY4-yne as two-step AfBP in article
One-step photoaffinity-based probes (Figure 6)						
50	[¹²⁵ I]11	Inhibitor	K _i : 15.1 ± 2.2 nM (DAT) K _i : 109 ± 14 nM (SERT) (nonradioactive iodine)	DAT (SLC6A3) SERT (SLC6A4)	[81]	Species: rat (labelling in human)
51	[¹²⁵ I]16b	Inhibitor	IC ₅₀ : 163 ± 25 nM (nonradioactive iodine)	DAT (SLC6A3)	[73]	Species: rat
52	[¹²⁵ I]-6	Inhibitor	K _i : 78 ± 18 nM (nonradioactive iodine)	DAT (SLC6A3)	[82]	
53	(±)-[¹²⁵ I]-SADU-3-72	Inhibitor	K _i : 3071 ± 497 nM (nonradioactive iodine)	DAT (SLC6A3)	[83]	
54	[¹²⁵ I]IAPEGlyMER	Inhibitor	IC ₅₀ : 200 ± 67 nM (nonradioactive iodine)	VMAT2 (SLC18A2)	[84]	Species: bovine
55	<i>trans</i> -[¹²⁵ I]TBZ-AIPP	Inhibitor	IC ₅₀ : 2100 ± 450 nM (nonradioactive iodine)	VMAT2 (SLC18A2)	[84]	Species: bovine
56	¹²⁵ I-labeled 4	Inhibitor	n.r.	MCT1 (SLC16A1)	[85]	
57	SAEATA-x14-biotin	Inhibitor	K _i : 2.69 ± 0.36 nM	ENT1 (SLC29A1)	[86]	
Two-step photoaffinity-based probes (Figure 7)						
58	Azidobupramine	Inhibitor	pK _i : 6.59 ± 0.06 (hNET) pK _i : 5.80 ± 0.07 (hDAT) pK _i : 6.99 ± 0.03 (hSERT) pK _i : 7.52 ± 0.03 (rSERT)	NET (SLC6A2) DAT (SLC6A3) SERT (SLC6A4)	[87]	Species: human and rat
59	Photoprobe 6	Inhibitor	K _i : 0.16 nM	SERT (SLC6A4)	[88]	
60	NVS-ZP7-6	Inhibitor	n.r.	ZIP7 (SLC39A7)	[89]	
61	mo56AZK	Pharmacochaperone	EC ₅₀ : 0.078 μM	NPC1 (SLC65A1)	[90]	
62	itraAZY	Pharmacochaperone	EC ₅₀ : 0.168 μM	NPC1 (SLC65A1)	[91]	
63	Photoprobe 1	Inhibitor	IC ₅₀ : 3 nM	MCT4 (SLC16A3)	[92]	Another photo-AfBP for MCT4 reported by Goldberg <i>et al.</i> (2023)

(Continues)

TABLE 1 | (Continued)

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
64	sCeMM1-PAP	Inhibitor	n.r.	MCT4 (SLC16A3)	[94]	but did not include synthesis [93]
65	AJ2-32	Inhibitor	IC ₅₀ : 2.5 μM	PHT1 (SLC15A4)	[95]	
66	Ing-DAYne	Inhibitor	n.r.	CAC (SLC25A20)	[96]	
One-step electrophilic affinity-based probes (Figure 8)						
67	[¹²⁵ I]MFZ-3-37	Inhibitor	n.r.	DAT (SLC6A3)	[97]	Species: rat
68	[¹²⁵ I]HD-244	Inhibitor	IC ₅₀ : 20 nM (nonradioactive iodine)	DAT (SLC6A3)	[74]	Species: rat; includes HD205 as covalent inhibitor in article
69	probe 2	Inhibitor	n.r.	AE1 (SLC4A1)	[98]	Species: sheep
Two-step electrophilic affinity-based probes (Figure 9)						
70	AMM-120	Inhibitor	n.r.	ANT1 (SLC25A4)	[79]	Species: bovine; includes AMM59 as covalent inhibitor in article
71	YY4-yne	Inhibitor	n.r.	MCP2 (SLC54A2)	[80]	Includes YY4 as covalent inhibitor in article
Bivalent ligands (Figure 10)						
72	Compound 17	Inhibitor	K _i : 180 ± 72 nM (NET) K _i : 6.6 ± 4 nM (DAT) K _i : 2600 ± 1100 nM (SERT)	NET (SLC6A2) DAT (SLC6A3) SERT (SLC6A4)	[99]	More bivalent inhibitors reported from same chemotype
73	Compound 30	Inhibitor	K _i : 8.5 ± 2 nM (NET) K _i : 1.0 ± 0.6 nM (DAT) K _i : 0.86 ± 0.79 nM (SERT)	NET (SLC6A2) DAT (SLC6A3) SERT (SLC6A4)	[99]	More bivalent inhibitors reported from same chemotype
74	Compound 10	Inhibitor	IC ₅₀ : 11 ± 3 nM (DAT) IC ₅₀ : 31 ± 11 nM (SERT)	DAT (SLC6A3) SERT (SLC6A4)	[100]	More bivalent inhibitors reported from same chemotype
75	Compound 2	Inhibitor	IC ₅₀ : 4.8 μM	SERT (SLC6A4)	[101]	More bivalent inhibitors reported from same chemotype
76	Compound 51	Inhibitor	[³ H]nisoxetine displacement at 10 μM: 65.1% (NET)	NET (SLC6A2) SERT (SLC6A4)	[102]	Species: rat

(Continues)

TABLE 1 | (Continued)

Cmpd nr.	Name	Functionality	Activity or affinity ^a	Target SLC	Reference	Remarks ^b
77	Compound 2	Inhibitor	K _i : 30.2 ± 4.29 nM (SERT) K _i : 0.64 ± 0.01 nM (SERT) K _i : 1676 ± 128 nM (DAT)	DAT (SLC6A3) SERT (SLC6A4)	[103]	More bivalent inhibitors reported from same chemotype
78	D-362	Inhibitor	K _i : 51.91 ± 4.54 nM	DAT (SLC6A3)	[104]	More bivalent inhibitors reported from same chemotype
79	Compound 5c	Inhibitor	IC ₅₀ : 14 ± 3 nM	SERT (SLC6A4)	[105]	Species: rat
80	Compound 11	Inhibitor	IC ₅₀ : 1.4 ± 0.1 μM (DAT) IC ₅₀ : 0.21 ± 0.02 μM (SERT)	DAT (SLC6A3) SERT (SLC6A4)	[106]	More bivalent inhibitors reported from same chemotype
PROTACs (Figure 11)						
81	d9A-2	Degrader	EC ₅₀ < 0.1 μM (in leukemia cell lines)	NHE1 (SLC9A1)	[107]	Can also partially degrade other SLC9 family members, also in other cancer cell lines
Photoswitchable inhibitors (Figure 12)						
82	(R)-6e	Inhibitor	pIC ₅₀ : 6.39 ± 0.08 (E) pIC ₅₀ : 5.78 ± 0.03 (Z)	GAT1 (Slc6a1)	[108]	Species: mouse
83	(R)-m-20a	Inhibitor	pIC ₅₀ : 4.65 ± 0.03 (E) pIC ₅₀ : 6.38 ± 0.04 (Z)	GAT1 (Slc6a1)	[109]	Species: mouse
84	ATT	Inhibitor	IC ₅₀ : 8.1 ± 1.1 nM (E, EAAT1) IC ₅₀ : 66.4 ± 4.9 nM (Z, EAAT1) IC ₅₀ : 0.9 ± 0.1 nM (E, EAAT2) IC ₅₀ : 12.7 ± 1.4 nM (Z, EAAT2) IC ₅₀ : 341.2 ± 19.5 nM (E, EAAT3) IC ₅₀ : 1132 ± 51 nM (Z, EAAT3)	EAAT1 (SLC1A3) EAAT2 (SLC1A2) EAAT3 (SLC1A1)	[110]	
85	p-MeO-azo-TBOA	Inhibitor	IC ₅₀ : 2.5 ± 0.4 μm (E) and 9.1 ± 1.5 μm (Z)	Glt _{TR} (bacterial glutamate transporter)	[111]	Species: <i>Thermococcus kodakarensis</i>
86	azo-escitalopram	Inhibitor	IC ₅₀ : 819 nM (E) and 18.9 nM (Z)	SERT (SLC6A4)	[112]	
87	compound 3	Inhibitor	IC ₅₀ : 5.36 μM (E) and 9.94 μM (Z)	GlyT2 (SLC6A5)	[113]	

^an.r.: not reported.^bProbes target the corresponding human SLC unless stated otherwise.

radiolabeled ligands, fluorescent probes are more accessible, cost-effective, and simpler to use, requiring only standard fluorescent microscopy for visualization [116]. Additionally, they provide greater flexibility in experimental design, allowing multiplexed imaging studies that enable the simultaneous visualization of multiple targets within a single sample. Improvements in probe affinity and selectivity, as well as fluorophore (photo)stability [117], have broadened their applicability across various methodologies, ranging from single-cell microscopy to high-throughput binding assays [118]. These advancements have led to a significant increase in the use of fluorescent probes that extend beyond visualizing protein expression and distribution to facilitate studies on (real-time) oligomerization, internalization, downstream signaling, and binding properties [119, 120].

Two primary approaches characterize the design of fluorescent probes. The first involves creating fluorescent ligands that mimic either endogenous or exogenous ligands, typically benefiting from smaller sizes and easier transport. The second approach employs a combination of a high-affinity parent ligand, an optimized linker, and a suitable fluorescent dye. For example, organic dyes like fluorescein, rhodamine, and cyanine are renowned for their bright fluorescence, enabling the detection of low-abundance proteins [121]. Their ability to conjugate with small molecules or peptides allows specific targeting, making them invaluable for fixed-cell imaging, flow cytometry, and other applications [115]. Additionally, near-infrared (NIR) fluorescent probes, which emit light in the 650–900 nm range, have gained importance in recent years [122–124]. NIR dyes offer deeper tissue penetration and reduced background due to the distinct wavelength when compared to the autofluorescence of endogenous biomolecules, making them ideal for *in vivo* imaging [115]. Furthermore, they enhance image resolution and signal-to-noise ratio compared to classic organic dyes. Although many challenges surrounding these probes have been tackled over the years, some still remain, like photobleaching and toxicity, driving continuous efforts to develop more stable and selective fluorescent probes. Additionally, the addition of fluorescent groups to high-affinity ligands can have a profound effect on the selectivity profile and (intracellular) localization of the probe, which warrants careful investigation. Through these studies, fluorescent probes have advanced the research of SLCs, prompting the development of numerous ligands across various SLC families. Moreover, gating-oriented live-cell distinction (GOLD) has been defined as an important mechanism for the development of cell-selective imaging probes in which transport of these probes is ATP-binding cassette (ABC) transporter- or SLC-mediated [125–127].

Specifically in case of glucose transporters (GLUTs, SLC2 family), many fluorescent probes have been reported and previously reviewed, highlighting their importance in biochemical and biomedical research [128–131]. This paragraph focuses on new advances in the field not discussed in these reviews. While probes had been developed to investigate glucose uptake, many suffered from limitations in terms of sensitivity, specificity, or applicability in complex biological systems. Seeking to address these shortcomings the Gao group introduced several innovative cyanine-based and glycoconjugate glucose probes, demonstrating high sensitivity and specificity for GLUT-mediated processes [132, 133]. Xu et al. developed two cyanine-based

glucose conjugates, among which Glu-1N-Cy3 (**1**, Figure 2), synthesized through direct amide coupling with cyanine fluorophores [132]. These probes showed higher sensitivity compared to traditional probes like 2-NBDG, making them valuable for theranostics and drug research. Expanding on this study, 6N-Gly-Cy3 (**2**, Figure 2) was designed, similar to the aforementioned probes with a cyanine substituted on the C-6 position instead of C-1 [133]. This probe demonstrated enhanced fluorescence and low cytotoxicity, rendering it suitable for live-cell imaging and as potential tracer for galactokinase metabolism. The cellular uptake of these probes was competitively inhibited by endogenous GLUT substrates, confirming their specificity for GLUTs. Additionally, 6N-Gly-Cy3 showed potential for single-molecule FRET-based studies due to its high fluorescence intensity. Wu *et al.* developed D-glucose-based fluorescent probes for super-resolution imaging of GLUTs in HeLa cells and erythrocytes [134]. These probes, such as the thio-glucose Glu-Alexa532 (**3**, Figure 2), offered high labeling density and specificity, potentially providing new opportunities to study glucose metabolism in different cell lines. In an attempt to circumvent low sensitivity and permeability of earlier reported fluorescent GLUT probes, Chen et al. synthesized N2 (**4**, Figure 2), a NIR fluorescent glucose analogue utilizing a DCPO dye [135]. N2 exhibited improved membrane permeability and high uptake in cancer cells overexpressing glucose transporter 1 (GLUT1, SLC2A1) compared to previously reported NIR-based probes, demonstrating its potential for cancer cell imaging and understanding cancer metabolism [136]. Similarly, several squaraine-based probes have been developed for selective optical imaging of cancer cells [40]. These dyes target the Warburg effect, where cancer cells exhibit increased glucose uptake via GLUTs. Conjugating squaraine dyes with glucose allows for selective absorption by cancer cells, triggering a “turn-on” fluorescence upon internalization through aggregation-mediated quenching. The unsymmetrical dye with α -glucose, ASq α Gl (**5**, Figure 2), showed superior imaging properties compared to its β -glucose counterpart. The dyes are nontoxic up to 20 μ M and provide bright fluorescence in cancer cells, making these probes promising for cancer imaging due to their specificity, strong NIR emission, and low toxicity. In addition, Jo et al. synthesized Glc-SiR-CO₂H (**6**, Figure 2), another NIR fluorescent tracer synthesized by conjugating glucosamine with silicon (Si) rhodamine (R) fluorochromes. This tracer effectively differentiated cancer cells from normal cells, providing a tool for measuring cytotoxicity of anticancer agents and monitoring anticancer effects [41]. Glu-1-O-DCSN (**7**, Figure 2), emitting deep-red fluorescence with a large Stokes shift, mimics natural glucose uptake and localizes in mitochondria via GLUT1-mediated transport, which are over-expressed in tumor cells [42]. *In vivo* studies in mouse models showed selective tumor accumulation without diffusion to other organs as well as the ability to cross the blood-brain barrier which suggests potential applications in tumor detection and brain disease imaging. Most recently, Tian et al. reported on precision detection and fluorescence image-guided surgery for oral squamous cell carcinoma using a novel probe, WZB117-IR820 (**8**, Figure 2) [43]. This fluorescent probe, conjugated with a GLUT1 inhibitor and a NIR dye, demonstrated high specificity in tumor detection and facilitated complete tumor resection in surgical mouse models. While certain limitations, like subtype specificity, quantitative detection, and *in vivo* toxicity remain,




FIGURE 2 | Molecular structures of fluorescent probes 1–15 targeting GLUTs and (V)MATs. In case of a fluorescent dye attached to a substrate or inhibitor, the fluorescent dye is highlighted in orange. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

these probes represent significant progress in imaging and characterizing GLUT-mediated processes in vivo, advancing diagnostic and therapeutic strategies.

Unlike GLUTs, which primarily regulate the influx of metabolic fuel, the (vesicular) monoamine transporters (V)MATs are primarily involved in the uptake and release of neurotransmitters. This difference in localization and substrate specificity requires

unique design principles for their respective molecular probes. The (V)MATs, consisting of NET, DAT, SERT, VMAT1 and VMAT2 have been extensively studied with the use of fluorescent probes as was recently reviewed by the Newman group as well as by the Sulzer team [137, 138]. Nevertheless, since publication of these reviews, several new fluorescent probes for these SLCs have been reported, addressing some challenges left unattended by previous probes. In an attempt to improve imaging resolution,

Wilson et al. developed two new analogues of APP⁺, PPP⁺ and BPP⁺ (**9** and **10**, respectively, Figure 2), and investigated their binding-induced fluorescence with SERT [44]. PPP⁺ and BPP⁺ exhibited turn-on fluorescence upon binding to SERT, demonstrating high sensitivity to their chemical environments. Molecular docking revealed that both probes access the nonpolar binding pocket of SERT, showing distinct fluorescence from intracellular accumulations. These findings provide valuable insights into SERT interactions and the potential application of these probes in differentiating serotonergic and catecholaminergic cells. Other fluorescent probes for visualizing (V)MATs stem from the development of so called fluorescent false neurotransmitters (FFNs). MFN103 (**11**, Figure 2), combines fluorescent and magnetic resonance properties to study dopamine storage and release in synaptic vesicles mediated by DAT and the vesicular monoamine transporter 2 (VMAT2, SLC18A2) [45]. SERTlight (**12**, Figure 2), designed for serotonergic neuron labeling, demonstrates high selectivity for SERT without significant binding to other receptors, providing stable, non-releasable optical signals compatible with genetically encoded sensors [47]. Furthermore, two new fluorescent probes, HT-CA and PA-CA (**13** and **14**, respectively, Figure 2), for imaging superoxide anion radicals (O₂^{•−}) in serotonergic neurons for SERT were reported by Wang et al. [48]. These probes enable real-time detection of oxidative stress in living mouse brains, revealing increased superoxide levels in depression models, providing the ability to monitor reactive oxygen species (ROS) dynamics in vivo to elucidate mechanisms underlying depression. The Newman group reported recent advancements focusing on developing fluorescent probes tailored for rapid detection of DAT in peripheral blood mononuclear cells [49]. Fluorescent probe GC04-38 (**15**, Figure 2), had high affinity and was selective for DAT, leading to reliable high-throughput detection of DAT-expression using flow cytometry from human and mouse samples, potentially serving as a non-invasive biomarker for conditions like Parkinson's disease.

Understanding SLC-mediated drug transport with fluorescent probes, can be important for predicting and managing such interactions and has been extensively reviewed very recently in case of liver transporters by Özvegy-Laczka et al. following the previous review of drug transporters by Fardel et al. [139, 140]. Newly reported fluorescent probes for these transporters are discussed below. In addition to their involvement in drug transport, organic anion transporting polypeptides (OATPs, SLC22 family) also play a pivotal role in the uptake of NIR dyes in cancer and immunology, enabling targeted imaging and therapy. Several new advances in this field have been reported over the years as has been reviewed by Zhang et al. [141]. More recently, the novel probe ZWZ-3, developed for melanoma imaging and therapy, exemplifies this important application. ZWZ-3 (**16**, Figure 2) is a hemicyanine-based probe that targets melanoma mitochondria via an OATP-dependent mechanism, inducing apoptosis and autophagy, significantly suppressing tumor growth both in vitro and in vivo [50]. Another innovative probe, CDrB (**17**, Figure 2), discriminates between T and B lymphocytes by utilizing distinct solute carriers, OATP1B3 (SLCO1B3) and the mitochondrial transporter SCA_{MC}-3L (SLC25A41), showcasing its potential for immune cell differentiation [51]. Additionally, IR-817 (**18**, Figure 2), a NIR fluorescent agent, targets melanoma mitochondria, inducing apoptosis and cell cycle arrest, significantly reducing tumor size in preclinical

models [52]. Both ZWZ-3 (**16**) and IR-817 (**18**) highlight the advantages of mitochondrial-targeting agents, while CDrB (**17**) underscores the importance of specific transporter mechanisms, both advancing diagnostic and therapeutic strategies in cancer and immunology. Recently, OATP1B1 and OATP1B3 (SLCO1B1 and SLCO1B3, respectively) were identified to mediate transport of rose bengal, a xanthene-based dye with anticancer properties (**19**, Figure 3) [53]. This selective uptake mechanism was determined in hepatic cancer cells overexpressing these transporters, as confirmed by confocal microscopy and flow cytometry highlighting the importance of these transporters in photodynamic therapy as targeted cancer treatment.

Like the OATPs, the human equilibrative nucleoside transporter 1 (hENT1, SLC29A1) is involved in the cellular uptake of chemotherapeutic drugs and has been studied using fluorescent ligand techniques. In 2023, Sui et al. reported the synthesis of SAENTA-Cy5 (**20**, Figure 3), a fluorescent probe designed for imaging with nanoscale resolution using direct stochastic optical reconstruction microscopy (dSTORM) [54]. This probe offers enhanced specificity and resolution over traditional antibody-based methods, reducing steric hindrance and improving labeling accuracy. SAENTA-Cy5 (**20**) enabled detailed visualization of hENT1 clustering, facilitating advanced studies of nucleoside transporter organization and their critical role in drug metabolism.

Since 2000, each SLC with a newly developed fluorescent probe, aside from those previously discussed, has been covered in only one or two articles. For example, Huynh et al. explored the synthesis of fluorescent probes based on excitatory amino acid transporter 1 (EAAT1, SLC1A3) inhibitor UCPH-101 [55]. Derivative UCPH-102F (**21**, Figure 3) is a coumarin-based analog that selectively inhibits EAAT1 with micromolar potency. While it emits fluorescence at physiological pH, its nonspecific binding complicated EAAT1 visualization in HEK293 cells to distinguish EAAT1 expression over EAAT3 (SLC1A1). Despite these limitations, the results hold promise for further developing UCPH-101 derivatives as fluorescent probes to study EAAT1. Very recently, 6FGA (**22**, Figure 3), a novel fluorescent glucose analogue, was designed to study sodium-glucose cotransporter (SGLT, SLC5) activity [56]. Synthesized by click conjugation of azido-D-glucose to a Cy5.5 dye, 6FGA (**22**) demonstrates nontoxic behavior and effectively measures transporter activity in cells, with uptake strongly dependent on sodium ions, indicating SGLT-mediated uptake. Compared to well-known fluorescent probe 2-NBDG, 6FGA (**22**) offers superior photophysical properties and sensitivity, making it a valuable tool for investigating glucose transport mechanisms in biological research. In 2020, the Wanner group reported the synthesis and evaluation of BODIPY-labeled ligands for murine γ -aminobutyric acid (GABA) transporters 1 to 4 (mGAT1-mGAT4, Slc6 family) [58]. These ligands were tested for their inhibitory potency across the different transporter subtypes. The study reports compounds with longer linkers, while more lipophilic, sterically demanding cyclic amines demonstrated higher inhibitory potency. Specifically, compound 10i (**23**, Figure 3), with a pentyl linker and methoxy group, showed improved potency for mGAT2-4 transporters, emphasizing the role of spacer length and structural modifications in enhancing activity. The same fluorescent probe emerged in a library screen in search




FIGURE 3 | Molecular structures of fluorescent probes 16–30 targeting SLCs. In case of a fluorescent dye attached to a high-affinity substrate or inhibitor, the fluorescent dye or moiety is highlighted in orange. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

of new inhibitors for glycine transporters GlyT1 (SLC, SLC6A9) and GlyT2 (SLC6A5) [57]. SC70-p (10i in the aforementioned study, **23**, Figure 3) showed the highest binding affinity for GlyT2. The study highlights the compound's potential as tools in fluorescence-based experiments to explore GlyT2 inhibition and related pharmacological processes.

Similarly, Zhu et al. explored the potential of tauro-nor-THCA-24-DBD (**24**, Figure 3) for the apical sodium ion-dependent bile

acid transporter (ASBT, SLC10A2), a fluorescent probe previously described as a substrate for several hepatic bile acid transporters [59]. ASBT-expressing *Xenopus* oocytes showed increased uptake of both the *R*- and *S*-isomers, indicating that tauro-nor-THCA-24-DBD (**24**) is a substrate for ASBT. The uptake was inhibited by taurocholic acid and elobixibat, an ASBT inhibitor, confirming ASBT-mediated transport. These findings support its potential as a tool for studying ASBT activity in intestinal tissues. The Wright group has advanced the

study of organic cation transporter 2 (OCT2, SLC22A2) with new fluorescent probes. Bednarczyk *et al.* reported NBD-TMA (25, Figure 3), a fluorescent substrate, that enables real-time measurement of cation transport in renal tubules, displaying high temporal and spatial resolution [61]. NBD-TMA (25) remains stable across physiological pH levels and unaffected by chloride ion concentration changes, indicating its robustness compared to traditional radiolabeled compounds. In a follow-up study, the same research group developed NBD-MTMA (26, Figure 3) as an improved version of NBD-TMA (25), which maintains stable fluorescence from pH 5.5 to 8.5, making it ideal for studying cation transport in biological systems without pH interference [62]. Both compounds are improved tools for investigating OCT2 functions and cellular transport mechanisms albeit with much less fluorescent intensity compared to fluorescein.

Regarding the mitochondrial Graves disease carrier (GDC, SLC25A16) and the fatty acid transport protein 3 (FATP3, SLC27A3) two new fluorescent probes were reported that are cell type specific via a GOLD mechanism. CDoB (27, Figure 3) distinguishes B cell developmental stages (progenitor, transitional, and mature) based on its fluorescence intensity [63]. CDoB localizes to mitochondria and correlates with SLC25A16 overexpression in mature B cells. The study demonstrates the ability of CDoB to selectively visualize mature B cells in spleen tissue, making it a useful tool for monitoring B cell maturation and identifying SLC25A16 as a potential biomarker for mature B lymphocytes. CDg18 (28, Figure 3) selectively targets M2 macrophages, which are associated with anti-inflammatory and tumor-promoting activities [64]. CDg18 distinguishes M2 cells by FATP3 transport, which is overexpressed in M2 macrophages. The probe accumulates in lipid droplets, allowing real-time visualization of macrophage polarization. Using CDg18 alongside the M1-selective probe CDr17 enables monitoring the reprogramming of M2 to M1 macrophages, which could be valuable for cancer treatment strategies targeting tumor-associated macrophages.

Aside from ENT1, the concentrative nucleoside transporters (CNTs, SLC28 family) have been the target for development of fluorescent probes as well due to their role in nucleoside homeostasis and transport of nucleoside-derived antiviral and anticancer drugs. One such probe, uridine-furan (29, Figure 3), was synthesized by the Pastor-Anglada group [65]. It demonstrated the ability to inhibit uridine uptake in HeLa cells expressing hCNT1 (SLC28A1) and hCNT3 (SLC28A3), showing high-affinity interaction in the low micromolar range. Confocal microscopy and flow cytometry confirmed uridine-furan's utility in detecting hCNT activity in living cells, suggesting its potential as a biomarker for transporter function *in vivo*.

Lastly, Kayano *et al.* recently reported the synthesis of fluorescent nicotianamine probe 15 (30, Figure 3), based on nicotianamine which is involved in the intestinal proton-coupled amino acid transporter 1 (PAT1, SLC36A1)-mediated uptake of iron ions in mammals [66]. The synthesis involved a click reaction of the protected 2'-hydroxy-nicotianamine with a dansyl group, creating the fluorescent probe. This probe effectively forms iron ion complexes that are transported via plant and mammalian transporters, ZmYS1 and PAT1, respectively.

This development facilitates the study of iron ion uptake mechanisms in plants and mammals, potentially offering insights into addressing iron deficiency issues.

Collectively, advances in the design and application of fluorescent probes for SLCs have greatly contributed to our understanding of the roles SLCs play in cellular homeostasis and how they are involved in pathological states, highlighting their utility for fundamental research and the translation of SLC insights into clinical applications.

3 | Covalent Inhibitors

Covalent inhibitors represent a powerful class of molecular tools used in chemical biology and drug discovery to elucidate interactions with and functions of proteins within complex biological systems [35, 142]. Unlike more traditional reversible inhibitors, covalent inhibitors form stable bonds with their target, enabling specific and permanent labeling of proteins in their native cellular environments. From a therapeutic perspective, covalent inhibitors have revitalized interest in targets previously considered undruggable. Many proteins deemed difficult to inhibit due to the absence of well-defined binding pockets can be targeted by exploiting covalent binding [143]. Moreover, irreversible binding can result in improved efficacy, reduced off-target effects, and lower drug resistance, making covalent inhibitors particularly attractive in the treatment of diseases like cancer, where mutation-driven resistance is a major challenge [144]. While irreversible binding is not without challenges (i.e., it can lead to on- and off-target toxicity) and the inherent reactive nature of covalent inhibitors can lead to metabolic instability, the field has made strides in evaluating and overcoming these pitfalls [145]. Several covalent drugs have already been approved, such as ibrutinib for chronic lymphocytic leukemia, Osimertinib for non-small cell lung cancer and nirmatrelvir as antiviral against COVID-19, demonstrating the clinical viability and therapeutic potential of this approach [146–148]. In addition to drug discovery, the implications of covalent inhibitors for chemical biology are noteworthy. These inhibitors provide powerful tools for examining the function of proteins in a cellular context, enabling studies of the dynamics of protein activity and regulation with high precision [149]. Furthermore, covalent inhibitors can serve as chemical probes to validate the function of newly discovered proteins and to explore the structural aspects of protein-ligand interactions for instance by stabilizing a protein-ligand complex which allows crystallization, contributing to our understanding of protein function at a molecular level [37]. The strategic design of covalent inhibitors includes the incorporation of a photo-reactive or electrophilic warhead on the inhibitor [150, 151]. Photoreactive warheads form highly reactive radical intermediates such as carbenes upon activation by light facilitating covalent binding, while electrophilic warheads are designed to covalently bind to nucleophilic amino acid residues of the target protein. This approach enhances the precision of this type of covalent inhibitors, also referred to as targeted covalent inhibitors (TCIs) [152], and thereby minimizes adverse effects and promotes drug safety profiles [153]. Through the application of covalent inhibitors, the molecular determinants for substrate selectivity, transport kinetics, and the impact of posttranslational

modifications on transporter function can be elucidated, thus advancing the understanding of SLC transporter biology. Subsequently, these insights provide opportunities for therapeutic intervention in various diseases through precise, selective and durable target engagement.

3.1 | Photoreactive Covalent Inhibitors

Besides serving as a template for functionalized probes such as AfBPs, which will be discussed in subchapters 3.1 and 3.2, photoreactive covalent inhibitors have been used primarily to characterize the molecular basis of the inhibitor-transporter binding. For this purpose, common photoreactive warheads such as aromatic and aliphatic diazirines, benzophenones, and aryl azides, are installed on existing SLC-targeting inhibitors [154, 155]. Below we will discuss the design and application of such inhibitors, as well as common challenges. While photoaffinity labeling of membrane fractions and the resulting identification of transport-related proteins has been attempted since the 80s [156], here we will focus on advances since 2000.

In an effort to find inhibitors for the glucose transporter type 4 (GLUT4, SLC2A4) in 2002, the Holman group reported two new bis-glucose derivatives integrating the photoactivatable trifluoromethyl diazirine warhead [67]. Introducing nitro- and iodo-substituents on the phenyl ring substituted with the warhead (31, Figure 4) resulted in 60 to 130-fold increased affinities for the GLUT4 compared to D-glucose. Moreover, these substitutions led to increased reactivity of the warheads upon determination of the rate of photolysis.

Another glucose transporter which was identified as a potential target for diabetes, the sodium-glucose co-transporter 1 (SGLT1, SLC5A1), has been studied with the use of several photoreactive covalent inhibitors by the Kinne group. Based on the high-affinity substrate arbutin, and the potent inhibitor phlorizin, the probes TIPDG (32, Figure 4) and BzG (33, Figure 4) were synthesized containing trifluoromethyl diazirine and benzophenone warheads, respectively [68]. These probes can be activated at 350–360 nm, avoiding protein-damaging wavelengths while exhibiting fully competitive inhibition in sodium-dependent D-glucose uptake assays, with K_i values comparable to their parent compounds. Furthermore, to illustrate the utility of this approach in exploring SGLT1 and related transporter proteins, MALDI-TOF MS analyses of TIPDG- and BzG-bound SGLT1 revealed efficient labeling of truncated loop 13, the proposed substrate and inhibitor recognition site. In addition, AOG (34, Figure 4), an alkyl glucoside-based probe, was introduced for SGLT1 [69]. In a similar manner, AOG was determined to bind to loop 13 indicating this part of the transporter as a binding domain for aglucone residues of inhibitors such as alkyl glucosides and phlorizin.

Similar to diazirines, benzophenones have an excitation range of 350 to 360 nm [157]. Despite being easier to incorporate, their bulkier nature tends to hinder proper interactions between the photoprobe and its biological targets, posing potential drawbacks [155]. This may explain why benzophenone is less utilized compared to diazirines when it comes to studying SLCs. Nevertheless, two TFB-threo- β -benzyloxyaspartic acid (TFB-TBOA)-based covalent inhibitors were reported bearing either a diazirine (compound 15, 35, Figure 4) or benzophenone (compound 16, 36, Figure 4).




FIGURE 4 | Molecular structures of SLC-targeting photoreactive covalent inhibitors 31–36. Photoreactive warhead is highlighted in blue. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

Figure 4) warhead targeting the EAATs (SLC1 family) [70]. The probes displayed submicromolar to micromolar inhibitory potency enabling the development of new TFB-TBOA-based probes for EAATs to understand binding mechanisms and for further therapeutic applications.

3.2 | Electrophilic Covalent Inhibitors

As mentioned above, where photoreactive inhibitors utilize light-activated chemistry, electrophilic covalent inhibitors rely on the inherent reactivity of an electrophilic warhead to form a covalent bond with a nucleophilic amino acid residue. For many years the Newman group has focused on the development

of new inhibitors and probes for MATs to elucidate the molecular mechanisms of these transporters and develop new therapeutics for a variety of neuropsychiatric conditions as well as drug abuse disorders. Based on previously reported one-step photoaffinity-based probes (photo-AfBPs), multiple other *N*-substituted tropane-based dopamine reuptake inhibitors were synthesized containing an electrophilic isothiocyanate warhead to initiate covalent binding [158]. Compound 26 (37, Figure 5) showed submicromolar potency and successfully binds to DAT in a wash-resistant manner indicating covalent attachment to an amino acid residue in the proximal binding site [71]. To further characterize potentially different MAT binding sites for tropane-based ligands, compound 16 (38, Figure 5) was designed. However, substitution with the aryl isothiocyanate on the 2-position of the




FIGURE 5 | Molecular structures of SLC-targeting electrophilic covalent inhibitors 37–49. Electrophilic warhead is highlighted in blue. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

benztropine scaffold resulted in significantly decreased inhibitory potency compared to the 2-substituted 3-phenyltropane counterparts, further suggesting different binding sites and limited tolerance of DAT for steric bulk at the 2-position of benztropines [72]. The different binding profiles of 3-phenyltropanes, benztropines and GBR-12909-based DAT inhibitors inspired the synthesis of rimcazole analogues as potential covalent inhibitors as the parent molecule showed distinct pharmacological and behavioral activity profiles in cocaine abuse animal models [73]. In this study, Cao et al. included synthesis of isothiocyanate derivatives with sub-micromolar inhibitory potency such as compound 14b (39, Figure 5). Based on the increased potency compared to corresponding the iodo-azido analogues, it was thought that during the binding experiments covalent interactions between the DAT and isothiocyanate analogues were formed leading to higher apparent IC_{50} values, however further characterization has not been reported.

Another phenyltropane-derived isothiocyanate covalent inhibitor was reported by Murthy et al. [74]. HD-205 (40, Figure 5), derived from the potent 2-naphthyl tropane WF-23, showed high affinity for all MATs in radioligand binding studies. The research highlights HD-205's potential to irreversibly label DAT, which was confirmed through the use of an iodinated analog, HD-244, as further discussed in subchapter 3.2. In the pursuit of dopamine-sparing cocaine antagonists crucial for mitigating the addictive properties of cocaine, Meltzer et al. proposed a novel strategy [75]. They designed irreversible inhibitor 6 (41, Figure 5) that covalently binds to DAT and leaves behind a small fragment that obstructs cocaine access while allowing dopamine transport. This innovative approach targets a reactive cysteine residue in DAT, aiming to selectively inhibit cocaine binding while preserving dopamine transport. Moreover, their compounds exhibited promising selectivity for DAT and demonstrated considerable inhibition of cocaine binding while allowing substantial dopamine uptake, offering a potential avenue for developing effective pharmacotherapeutics to combat cocaine abuse.

Besides the MATs, extensive research has also been done on the covalent inhibition of amino acid transporters, focusing on the alanine/serine/cysteine transporter 2 (ASCT2, SLC1A5) and L-type amino acid transporter 1 (LAT1, SLC7A5), both crucial in cancer metabolism. Oppedisano *et al.* explored the inhibition of ASCT2 using 1,2,3-dithiazoles (42, Figure 5) [76]. Their findings revealed that several derivatives inhibited over 50% of glutamine transport at 20 μ M, with inhibition reversible by 1,4-dithioerythritol, suggesting mixed sulfide formation with cysteine residues on the transporter. Kinetic studies indicated noncompetitive inhibition, likely through covalent binding to cysteines outside the substrate site, with Cys207 or Cys210 identified as potential targets. Complementing this, Napolitano et al. targeted LAT1, overexpressed in many cancers. Herein, several dithiazole and dithiazine compounds (42 and 43, respectively, Figure 5) were screened, discovering multiple ligands with significant inhibitory effects on LAT1 [159]. The inhibition mechanism involved disulfide bond formation with LAT1's cysteine residues, particularly Cys407, confirmed by docking simulations and mutant studies. Effective inhibitors induced cell death in cancer cells with high LAT1 expression, highlighting their potential as anticancer agents. These studies collectively advanced the understanding of targeting amino acid

transporters in cancer therapy, offering promising opportunities for the development of novel anticancer drugs by inhibiting crucial transport mechanisms in tumor cells.

Inspired by photoaffinity labeling experiments previously reported for ASBT (SLC10A2) [160] González et al. reported the synthesis of electrophilic chenodeoxycholic acid (CDCA) derivatives with the purpose to identify the bile acid binding sites of ASBT in a more specific manner [77]. 3β -Cl-CDCA and 7α -Ms-CDCA (44 and 45, respectively, Figure 5) were found to be potent and selective irreversible inhibitors of ASBT that bind to the transmembrane domain 7 (TM7) cleft of the transporter as was reported for rabbit ASBT with taurocholic acid (TCA) derivatives [160]. However, no mechanistic evidence was found for a covalent nature of irreversible binding. Another chemotype of inhibitors was found to covalently modify ASBT and significantly reduce TCA uptake in Caco-2 cells [78]. Two theaflavins, theaflavin-3-gallate (TF2A, 46, Figure 5) and theaflavin-3'-gallate (TF2B, 47, Figure 5) competitively inhibited ASBT activity without affecting cell viability. It was proposed that these compounds exert their inhibitory effect through the oxidation of their benzotropolone rings, leading to covalent binding with ASBT's cysteine residues. Hence, these theaflavins could be potential therapeutic agents for lowering plasma cholesterol levels by modulating bile acid transport and might help in designing more effective dietary strategies for preventing hypercholesterolemia.

Based on an extensive chemical library screen, epoxycyclohexenedione (ECHD)-type of compounds were identified to be potent inhibitors consisting of a new chemotype for the mitochondrial adenine nucleotide translocator 1 (ANT1 or AAC1, SLC25A4) [79]. Compound AMM-59 (48, Figure 5), was found to inhibit ADP uptake in bovine heart submitochondrial particles. In addition, these type of compounds were hypothesized to form covalent bonds because of the electrophilic epoxide and α,β -unsaturated carbonyl within the structure. By testing the reactivity against ethanethiol in thin-layer chromatography experiments, potential reactivity against cysteines was confirmed and further explored by converting AMM-59 into a two-step AfBP (further discussed in subchapter 3.2). Similarly, a broad proteomic screen using a fragment-based approach identified YY4 (49, Figure 5), with an α -chloroacetamide warhead, as a covalent inhibitor targeting Cys54 of the mitochondrial pyruvate carrier subunit 2 (MPC2, SLC54A2) [80]. These findings also prompted the development of a YY4-based two-step AfBP as a new tool to study MPC2 as a cellular engagement probe in Western blot and mass-spectrometry-based proteomics, which are highlighted in subchapter 3.2. Besides serving as a stepping stone towards further research, covalent inhibitors have yielded a wealth of information on SLC structure, function and therapeutic potential.

4 | Affinity-Based Probes (AfBPs)

AfBPs are essentially covalent ligands that are able to not only bind the target irreversibly, but also tag it with a specific purification or visualization moiety. AfBPs have evolved from the principles underlying activity-based probes (ABPs), which were initially created to target enzymes [161]. Serving as invaluable

tools for navigating the complex pathways of cellular transport, AfBPs typically entail a sophisticated design comprising a ligand with high-affinity binding to a target protein and a reactive group facilitating covalent binding between the ligand and the target as the previously discussed covalent probes [162, 163]. However, they are differentiated through the inclusion of a reporter group which enables visualization, quantification, and/or purification of the labeled target protein in biochemical assays.

Similar to covalent inhibitors, AfBPs utilize two types of reactive groups: electrophilic or photoreactive warheads. Depending on the labeling strategy of the reporter groups, AfBPs are categorized into one-step or two-step probes. In the one-step approach, the reporter group is directly attached to the AfBP. Common reporter groups used in one-step probes include radioactive isotopes, fluorophores, and biotin tags. While radioactive isotopes offer benefits such as small size, high sensitivity, and ease of detection, they also pose environmental risks, sometimes short half-lives, and the need for specialized handling. Biotin and fluorophores aid in the enrichment, isolation, and detection of target proteins but can be bulky and potentially interfere with interactions between the probe and target protein.

On the other hand, two-step probes often employ a click handle, such as a terminal alkyne or aliphatic azide moiety, which can be functionalized after the initial covalent binding of the probe to the target protein, typically through bio-orthogonal ligation reactions [155, 164]. This approach is notable for the small size and easy incorporation of click handles, minimizing potential disruptions to crucial ligand-target interactions and preserving biological activity [165]. Additionally, these functional groups are compatible with biological systems, allowing for in vivo applications. However, this method has the disadvantage of added complexity and time requirements. Furthermore, the use of potentially cytotoxic reagents in bio-orthogonal conjugation reactions necessitates careful handling to mitigate risks. Therefore, AfBPs are versatile tools for investigating cellular transport pathways, employing either electrophilic or photoreactive groups for covalent binding to SLCs and using one-step or two-step strategies for reporter group labeling.

4.1 | Photoaffinity-Based Probes

One-step photo-AfBPs gained importance in the 1970s and 1980s for mapping receptor-ligand interactions. With regard to studying SLCs, most one-step photo-AfBPs that were developed, target MATs (including NET, DAT, SERT and VMATs) and GLUTs, both of which have been extensively reviewed elsewhere [166–171]. The probes that have not been discussed in these reviews as well as their applications are discussed below.

Looking to expand the tropane-based toolbox for MATs the Newman and Vaughan group incorporated a photoreactive aryl azide on the 3 β -position to give [125 I]11 (**50**, Figure 6) [81]. Using SDS-PAGE experiments it was shown that both hDAT and hSERT were photolabeled, indicating a shared binding site with cocaine for these SLCs. This also highlighted the importance of positioning the photoreactive warhead away from the tropane pharmacophore to achieve effective labeling. Additionally, another class of dopamine reuptake inhibitors was

investigated by the Newman group, based on rimcazole, an antipsychotic agent which was in clinical trials for treatment of acute schizophrenia [73]. Establishing a small structure–activity relationship led to the synthesis of photoaffinity probe [125 I]16b (**51**, Figure 6). The probe was shown to effectively and covalently label hDAT in western blot experiments and was used in further studies of the hDAT binding site.

More recently, Lapinsky et al. synthesized pyrovalerone-based ligands, substituting the aromatic ring with a photoreactive azido group to create [125 I]-6 (**52**, Figure 6), which labeled and bound hDAT with nanomolar affinity [82]. In contrast to the tropane-based one-step photo-AfBPs, the photoreactive group could be incorporated directly on the pharmacophore of ($\pm$)-[125 I]-SADU-3-72 (**53**, Figure 6), a probe based on the antidepressant bupropion, which was synthesized to investigate its interactions with DAT and nicotinic acetylcholine receptors [172].

In addition to the previously reviewed inhibitors, substrates and photoaffinity labeling agents for VMATs, two additional probes have been reported based on the nanomolar-affinity inhibitors reserpine and tetrabenazine [168]. [125 I]IAPEGlyMER (**54**, Figure 6) and *trans*-[125 I]TBZ-AIPP (**55**, Figure 6) both labeled VMAT2 in bovine chromaffin granules, providing tools to further study the binding site of these inhibitors [84]. Moreover, decreased labeling with *trans*-[125 I]TBZ-AIPP (**55**) in the presence of ATP provided further indications of the transporters' conformational change upon generation of a proton gradient in the vesicles.

In 2005, AstraZeneca published the discovery of MCT1 (SLC16A1) as the target of immunomodulating quinazolinoliones with the use of 125 I-labeled 4 (**56**, Figure 6) in SDS-PAGE and proteomics experiments [85]. Upon identification of MCT1 as a target for inhibiting T-lymphocyte proliferation, many studies have followed to map the SLC's role in the tumor microenvironment and to design novel inhibitors [173].

Before the crystal structure of hENT1 was elucidated in 2019, the Buolamwini group made multiple efforts to explore the inhibitor binding interactions of ENT1. For this purpose, the well-characterized ENT1 inhibitor NBTI was converted into photo-AfBP SAEATA-x14-biotin (**57**, Figure 6) by substituting the aromatic nitro group with an azide and addition of a linker attached to a biotin reporter group on the 5'-OH of the original ribose ring similar to the fluorescent derivative 5-(SAENTA)-x8-fluorescein [86, 174]. SAEATA-x14-biotin (**57**) was able to cross-link ENT1 in a wash-resistant manner and could be visualized using streptavidin detection after SDS-PAGE.

The first two-step photo-AfBP for MATs, azidobupramine (**58**, Figure 7), was reported in 2016 [87]. As an analogue of the tricyclic antidepressant imipramine, azidobupramine was designed to covalently target hMATs using an aryl azide. Moreover, the addition of an alkyne tag at the terminal amine allowed for copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) to attach reporter moieties, such as fluorophores. This novel probe maintained binding affinity comparable to various tricyclic antidepressants while enabling the visualization of azidobupramine-SERT complexes in membrane fractions with induced SERT expression as well as in living cells. The Lapinsky




FIGURE 6 | Molecular structures of SLC-targeting one-step photoaffinity-based probes 50–57. Photoreactive warhead and reporter group are highlighted in blue and orange, respectively. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

group built upon this pioneering work to further design multifunctional tools derived from clinically approved antidepressants. Leveraging escitalopram's unique pharmacological properties, such as its high affinity for both the S1 and S2 hSERT binding sites, they synthesized a series of clickable photoprobes [88]. Photoprobe 6 (**59**, Figure 7), featuring a benzophenone moiety and a ligation handle at the C-5 position of escitalopram, demonstrated a remarkable 11-fold improvement in hSERT binding affinity compared to the parent compound and was clickable to IRDye 800CW. Western blot analysis revealed that the probe labeled purified hSERT, facilitating structure-function studies and imaging applications involving hSERT. These advancements in the field of neuropsychopharmacology offer a promising approach for identifying antidepressant target proteins without using radioactive isotopes, marking a significant step forward in drug discovery and understanding antidepressant mechanisms.

In search of biological targets in the Notch signaling pathway, a study by Nolin et al. employed a photoaffinity labeling approach [89]. As a result of siRNA knockdown experiments and equipping a newly identified inhibitor of Notch signaling with a diazirine and terminal alkyne (NVS-ZP7-6, **60**, Figure 7), zinc transporter 7 (ZIP7, SLC39A7) was validated as target to disrupt Notch protein trafficking, induce ER stress, and trigger apoptosis in T cell acute lymphoblastic leukemia (T-ALL) cells. These findings show ZIP7's critical role and open avenues for

novel cancer therapies by modulating Notch signaling, particularly in cancers with dysregulated Notch pathways.

The Ohgane group investigated NPC intracellular cholesterol transporter 1 (NPC1, SLC65A1), another SLC highly implicated in disease [90]. Inherited mutations in the protein can lead to the rare Niemann-Pick disease type C by causing folding defects ultimately leading to lysosomal and late endosomal cholesterol accumulation [175]. This study on pharmacological chaperones for NPC1 focused on oxysterol derivatives, which demonstrated significant potential in repairing NPC1-I1061T protein misfolding. Photocrosslinking followed by SDS-PAGE experiments with the oxysterol-derived two-step photo-AfBP mo56AZK (**61**, Figure 7) and N-terminal domain-deleted NPC1 revealed that these molecules interact with a non-N-terminal domain sterol-binding site on NPC1, suggesting the presence of a second sterol-binding site. This interaction aids in the proper folding and maturation of the mutant protein, improving its localization and function within cells. Additionally, in a follow-up study an image-based screening method was used to identify potential new chaperones for NPC1 from a drug-repurposing point of view [91]. Itraconazole, a known antifungal, emerged as a potential pharmacochaperone to the NPC1-I1061T mutant protein amongst other azole antifungal compounds. This suggested that the *N,N*-diaryl piperazine moiety in these molecules may be important for the misfolding rescue properties. By converting itraconazole into the photo-crosslinking compound itraAZY (**62**, Figure 7) and the use




FIGURE 7 | Molecular structures of SLC-targeting two-step photoaffinity-based probes 58-66. Photoreactive warhead and ligation handle are highlighted in blue and orange, respectively. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

of competitive binding studies, it was confirmed that this anti-fungal binds directly to NPC1-I1061T and shares binding sites with oxysterol-based chaperones near the sterol-sensing domain. Although less effective at reducing cholesterol accumulation than oxysterol-derived chaperones or the histone deacetylase inhibitor LBH-589, itraAZY provides a promising starting point

for developing pharmacological chaperones to treat NPC1-related diseases through targeted medicinal chemistry efforts.

In search of new selective inhibitors for the monocarboxylate transporter 4 (MCT4, SLC16A3), AstraZeneca developed photoprobe 1 (**63**, Figure 7), a clickable photo-AfBP that retains

cellular biological activity in the MCT4-driven lactate efflux assay [92]. Photoprobe 1 (**63**) was employed in reverse competition assays with AZ1422, demonstrating its utility in visualizing probe localization through fluorescence imaging. In live NCI-H358 cells, photoprobe 1 enabled the confirmation of cellular localization of AZ1422. This study shows the importance of photoprobe 1 in validating target engagement and elucidating the mechanism of action for therapeutic compounds targeting MCT4 in cancer. In another study, by the Superti-Furga group, the photoaffinity probe sCeMM1-PAP (**64**, Figure 7) was developed to study SLC16A3 [94]. This probe, derived from the selective SLC16A3 inhibitor sCeMM1, incorporates a diazirine moiety for covalent crosslinking and an alkyne handle for reporter tag conjugation. sCeMM1-PAP demonstrated biological activity similar to sCeMM1 but with increased toxicity at higher concentrations. Chemoproteomic analyses using sCeMM1-PAP revealed the probe's high selectivity for SLC16A3, confirming its effectiveness in distinguishing target proteins from off-targets within the proteome, thereby validating the used paralog-dependent isogenic cell assay (PARADISO) as a cell-based assay approach in drug discovery screening for SLCs.

Using a fully functionalized fragment (FFF) approach, the Parker group reported the development of the first inhibitors that disrupt all functions of the peptide transporter 4 (PHT1, SLC15A4) [95]. Based on the candidate hits several inhibitors and a two-step photo-AfBP AJ2-32 (**65**, Figure 7) were developed to perform target engagement experiments. The inhibitors were validated as having significant potential for treating inflammatory and autoimmune conditions. The inhibitors, particularly AJ2-30, were shown to reduce the production of interferons (IFN- α , IFN- β , and IFN- γ) and suppress early mTOR signaling, which mimics the functional loss of SLC15A4. This suggests that targeting SLC15A4 could be effective in managing lupus and other autoimmune diseases. Another photoreactive and clickable probe by Parker *et al.* was used to determine the involvement of the molecular targets of Ingenol mebutate (IngMeb), a drug for actinic keratosis [96]. Ing-Dayne (**66**, Figure 7) was designed with

a diazirine group for crosslinking and despite its reduced potency, retained sufficient biological activity for proteomic studies. Using mass spectrometry, the probe identified multiple protein targets, notably carnitine/acylcarnitine carrier (CAC, SLC25A20), a mitochondrial transporter. Ing-Dayne revealed that IngMeb blocks SLC25A20, impairing fatty acid oxidation and causing mitochondrial dysfunction, suggesting a new mechanism for IngMeb's therapeutic effects.

4.2 | Electrophilic Affinity-Based Probes

Electrophilic AfBPs for SLCs have also provided valuable insights into transporter ligand-binding sites, though to a lesser degree compared to photoaffinity AfBPs. For this type of probes isothiocyanate is the most frequently used reactive electrophilic warhead. In addition to the aforementioned one-step photo-AfBPs developed for the MATs, two tropane-based probes were synthesized to covalently bind the transporters in rat striatal membranes in a covalent manner [74, 97]. These probes, [125 I]MFZ-3-37 (**67**, Figure 8) and [125 I]HD-244 (**68**, Figure 8), both bound rDAT albeit with off-target labeling of multiple other proteins. The off-target labeling, which was not reported for the aryl azide analogue probes, was attributed to the reactivity of the isothiocyanate warhead.

To enable the identification of a putative binding pocket of cholesterol in the anion exchanger 1 (AE1, SLC4A1), Moriyama *et al.* demonstrated a novel chemical tagging approach in erythrocyte membranes using the thiourea of probe 2 (**69**, Figure 8) [98]. The study highlighted the possibility of analyzing lipid-protein interactions within complex membrane protein systems, paving the way for comprehensive proteomic analyses and potential therapeutic developments.

The exploration of two-step electrophilic affinity-based probes for SLCs was pioneered by Aoyama *et al.* in 2018 [79]. In this study, ECHD-like compounds, specifically the AMM-59 above




FIGURE 8 | Molecular structures of SLC-targeting one-step electrophilic affinity-based probes 67–69. Electrophilic warhead and reporter group are highlighted in blue and orange, respectively. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]




FIGURE 9 | Molecular structures of SLC-targeting two-step electrophilic affinity-based probes 70 and 71. Electrophilic warhead and ligation handle are highlighted in blue and orange, respectively. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com/doi/10.1002/med.70009)]

(48, Figure 5) and AMM-120 (70, Figure 9), were investigated as potent inhibitors of bovine ANT1 (SLC25A4, old nomenclature of AAC1 used in original article) [79]. Analysis by SDS-page and proteomics experiments of AMM-120-bound ANT1 revealed that these compounds inhibit ANT1 function primarily by forming covalent bonds with amino acid residue Cys57 and secondarily with Cys160 of the protein. Moreover, prolonged exposure to high concentrations of ECHDs induced aggregation of ANT1 suggesting a significant structural alteration. Importantly, this aggregation was not attributed to intermolecular disulfide linkages but rather to hydrophobic stacking mediated by probes bound to Cys57 and possibly Cys160. This phenomenon represents a unique characteristic of ECHDs, presenting a novel avenue for studying ANT1 transporters and offering insights into their structural dynamics and potential regulatory mechanisms.

Recently, Yamashita et al., also presented a two-step AfBP approach utilizing the aforementioned α -chloroacetamide (α CA) inhibitor YY4 (49, Figure 5) to selectively modify amino acid residue Cys54 within MPC2 (SLC54A2) [80]. YY4-yne (71, Figure 9), facilitated the study of MPC2 but not MPC1 in living cells using Western blot analysis as well as proteomics techniques showing the selective nature of the probe. Moreover, their findings shed light on the mechanism of action of UK-5099, a MPC2 inhibitor with hypothesized covalent reversible mechanism of action, suggesting this inhibitor may also interact with Cys54.

5 | Bitopic Probes

Bitopic probes such as bivalent ligands, molecular glues and PROTACs are molecules designed to establish dual engagement within one protein or between two proteins. The probes, bearing two high-affinity binding moieties for their respective protein, offer a wide arrange of strategies to study proteins. Such probes may target combined orthosteric and allosteric binding sites on one protein, which may enhance selectivity, induce protein-protein interactions or cause targeted protein degradation [176–179].

Bivalent strategies have been employed to enhance inhibitor-protein interactions on SLCs. By simultaneously engaging with multiple substrate recognition sites on transporters, bivalent probes may induce interactions with increased affinity compared to individual monovalent molecules [180]. In addition, achieving selectivity can be crucial, as multiple SLCs within one family often exert various physiological effects. Since for many

SLCs there are multiple binding sites, the length of the linker connecting the two binding components in bivalent ligands could offer a way to fine-tune the selectivity of these ligands for specific transporter types as previously described for GPCRs [181]. Theoretically, their specificity can be attained through two potential bridging mechanisms [182]. In the first case, the bivalent ligand is linked with a spacer of suitable length, facilitating both ligands to attach to similar or identical adjacent recognition sites. With the correct linker configuration, the bivalent binding is favored, while inadequate spacer length permits only monovalent binding. The second bridging approach occurs when the second ligand binds to an accessory site of a neighboring protein. However, this is specific to receptors and has not yet been shown for SLCs [183].

Targeted protein degradation (TPD) has emerged as one of the most significant developments in chemical biology and drug discovery over the past years [178, 184, 185]. A prominent class within TPD are PROTACs, which have emerged as a novel method that deviates from conventional therapeutic strategies based on optimizing ligand-protein occupancy [186]. PROTACs are heterobifunctional small molecules, comprising two ligands interconnected by a linker. One ligand moiety participates in the recruitment and binding of the protein of interest (POI), while the other engages with an E3 ubiquitin ligase. The simultaneous binding of the POI and E3 ligase leads to the ubiquitination of the POI, initiating its subsequent proteasomal degradation and recycling of the PROTAC for reuse. Suitable protein candidates for TPD typically exhibit characteristics that promote disease-causing gain of function [187]. Structurally, effective PROTAC targets require a small molecule binding site accessible to an E3 ligase [188]. Additionally, it is beneficial to have an unstructured section that makes engagement with the proteasome easier [189]. Despite these common requirements, proteins with scaffolding roles, mutations inducing resistance to targeted treatments, or those traditionally deemed “undruggable” can also be excellent candidates for PROTAC intervention [190, 191]. As a result, the catalytic nature of PROTACs and the resulting depletion of a POI could circumvent challenges such as drug-resistance and off-target effects observed with small-molecule inhibitors.

5.1 | Bivalent Ligands

Where in previous paragraphs examples from various SLC's were presented, the application of bivalent ligands in SLC

research focused solely on MATs. In the early 2000s, the Kozikowski and the Cashman groups designed multiple novel dimeric MAT inhibitors based on 3,4-disubstituted piperidines and phenyl tropanes as reviewed previously [192–196]. Nielsen *et al.* extended the work on bivalent phenyltropanes by designing a number of probes linked with amide-connected aromatic spacers (**72**, Figure 10) or ester connected triazole linkers (**73**, Figure 10), which displayed higher affinity for MATs compared to parent monovalent compound RTI-31 [99]. This supported the hypothesis reported by Fandrick *et al.* that incorporating longer linkers in bivalent phenyltropanes can reverse the low DAT inhibitory potency observed in monovalent

compounds suggesting the existence of a secondary tropane binding site (S2 binding site) in addition to the primary binding site (S1 binding site) [195]. Subsequent work by Meltzer *et al.* however challenged the hypothesis, reporting tropane-based bivalent ligands (**74**, Figure 10) that were less effective than monovalent counterparts despite maintaining high potency, suggesting the absence of proximal binding sites [100].

The same effect is also observed for bivalent ligands based on imipramine, an antidepressant with potential anticancer effects (**75**, Figure 10). Although the bivalent ligands had higher potential anticancer effects compared to the monomeric imipramine,




FIGURE 10 | Molecular structures of exemplary SLC-targeting bivalent probes 72–80. Monovalent ligand moieties (connected by a linker) are highlighted in blue and orange. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

a two-fold decreased affinity was found against SERT [101]. This indicates that bivalent ligands should express specific structural characteristics to bind to MATs with high affinity. In addition, a follow-up computational study predicted the S2 site approximately 10–12 Å above S1, after which imipramine-based bivalent probes were optimized accordingly to facilitate binding to both sites simultaneously [197]. As opposed to previous studies, the dimers with the shortest chain length had the highest potency, albeit all with significantly lower affinity compared to monovalent imipramine. Importantly, it was proposed that S2 facilitates a secondary, low-affinity allosteric site for inhibitors and interaction of inhibitors with this site influences the rate at which molecules detach from their primary binding sites. This is thought to occur due to a mechanism involving the physical obstruction of the exit pathway [198]. The study supported this concept by showing that expanding the S2 site through mutations led to an increased potency of inhibitors, implying that S2 may indeed negatively contribute to inhibitor potency.

Several studies have debated the roles of S1 and S2 subsites in MATs with respect to the pharmacological effects of inhibitors. While S1 has been extensively studied, the specific role of S2 remains less clear [199–203]. Notably, the S2 site has been described as being more tolerant than the S1 site, indicating that it can accommodate structural modifications to ligands with less impact on binding affinity [198, 204, 205]. Based on this observation, Banala et al. synthesized escitalopram derivatives, identifying compounds such as compound 51 (**76**, Figure 10) with selective affinity for S2 over S1 [102]. This study stresses the possibilities of bulky modifications and optimization of already known potent inhibitors that may have selectivity towards S2, and may be a starting point for further S2 studies.

Bivalent probes have also been used to elucidate substrate recognition mechanisms in MATs using homo- or heterobivalent probes based on dopamine and serotonin [103, 104]. The study by the Strömgaard group demonstrated an up to 3800-fold increased affinity for bivalent probes such as compound 2 (**77**, Figure 10) when compared to their monovalent parent substrate from which subsequent docking studies also suggested simultaneous binding to both S1 and S2 [103]. In addition, they demonstrated by using the bivalent probes together with mutational analysis that non-conserved residues in binding sites do not aid in substrate selection during binding. Additionally, Schmitt et al. synthesized MAT substrate-based bivalent probes like D-362 (**78**, Figure 10) that when subjected to binding assays with mutated transporters revealed a higher affinity towards inward-facing transporters [104]. Most recently, Ruchala et al. explored the functional characterization of various variants of *N*-octyl 4-methylamphetamine and related bivalent compounds at DAT and SERT. The use of psychostimulant-derived bivalent probes in addition to the aforementioned inhibitor and substrate-based probes revealed that certain bivalent compounds (**80**, Figure 10) exhibited potent inhibitory activity at DAT and SERT, offering insights into their potential therapeutic applications, including managing cocaine addiction [106].

Besides targeting only SLCs, bivalent ligands with a different mechanism of action to target two different proteins including a transporter and a GPCR were reported. Several bis-indole derivatives based on serotonin using propylpiperazine linkers

(**79**, Figure 10) were synthesized to achieve a dual inhibitory activity at both SERT and 5-HT_{1A} receptor [105]. With the combined use of radioligand binding assays and molecular docking multiple bivalent probes with nanomolar affinity for both targets were found creating a starting point for new inhibitors with this dual transporter-receptor binding mechanism.

5.2 | PROTACs

While many advances in the field of TPD have been made, with the first examples entering the clinic [206], targeting multi-pass membrane proteins has remained challenging. Reported studies in the field of TPD are predominantly focused on targeting nuclear, cytoplasmic, and single-pass transmembrane proteins, while SLCs and other transmembrane protein families have been underexplored as targets for PROTACs. This is mainly due to their complex transmembrane topology and diverse subcellular localizations, which both can be challenging for efficient engagement with the E3 ligase and hence the proteasome. However, in 2020, this notion was challenged, demonstrating the successful degradation of multi-pass transmembrane proteins, particularly those from the SLC family, using the genetically encoded dTAG degradation system [107]. In addition, this led to the design and synthesis of d9A-2 (**81**, Figure 11), a PROTAC targeting the sodium-hydrogen antiporter 1 (NHE1, SLC9A1), and to a lesser degree, other members within the SLC9 family. The PROTAC demonstrated efficacy in initiating proteasomal degradation by the CRL4^{CRBN} E3 ligase complex. Moreover, it was shown that d9A-2 (**81**) is able to induce cytotoxicity in various cancer cell lines via disturbing the intracellular pH homeostasis in which the PROTAC was most potent in leukemic cancer cells.

6 | Photoswitchable Inhibitors

The development of photoswitchable inhibitors, also known as photochromic inhibitors, represents a significant advancement




FIGURE 11 | Molecular structures of SLC-targeting PROTAC d9A-2 (**81**). Ligand moiety binding to the POI (sodium-hydrogen antiporter 1, NHE1, SLC9A1) and E3 ligase are highlighted in orange and blue, respectively. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

in molecular pharmacology. Photoswitchable compounds undergo structural changes upon irradiation with light of a certain wavelength, leading to significant alterations in their affinity or intrinsic activity towards the target [207]. This enables precise spatiotemporal control over their activity, allowing reversible activation and deactivation of inhibitors at specific protein targets at any time using light. The use of external stimuli to control ligand activity provides powerful tools for monitoring and altering cellular processes in living cells and organisms non-invasively and therefore may enhance our understanding of transporter functions and offer valuable insights into transporter-ligand interactions [208].

Two primary strategies are employed to manipulate the activity of bioactive molecules using light, which can be either irreversible or reversible. The first involves employing photo-reactive components, such as *o*-nitrobenzyl or coumarin, to temporarily deactivate a physiologically active small molecule, producing a “caged” compound that is inactive on the target [209]. Exposure to light of a specific wavelength irreversibly releases the ligand by breaking the bond and initiates a biological response in a rapid and localized manner [210]. Another approach is through the incorporation of molecular photo-switches, such as diarylethenes [211] and azobenzenes [212]. Upon irradiation, the photoswitch-incorporated molecules are able to undergo *cis-trans* isomerization, leading to changes in their 3D conformation and properties [213]. While these structural alterations can result in variations in the biological activity of the compounds, this is not a trivial matter. Azobenzenes remain the predominant choice among photoswitches, mainly because they demonstrate favorable characteristics such as accessible synthesis, small size, metabolic stability, as well as rapid isomerization with high quantum yields and little photobleaching [212]. These characteristics make them highly effective for investigating various transmembrane proteins, such as

GPCRs [214] and ion channels [215]. For azobenzenes, the linear and flat *trans* (*E*)-form tends to display higher thermodynamic stability than the *cis* (*Z*)-form, which is also more polar and soluble in aqueous environment [216, 217]. Typically, the ligand is converted to the less stable isomer by one wavelength of light. Subsequently, it can either thermally revert to its stable form in the dark or be switched back to the more thermodynamically stable isomer using a second wavelength of light.

While the field of photopharmacology is still in its infancy for SLCs, the Wanner group has pioneered it with the development of the first photochromic inhibitor targeting the murine GAT1 (mGAT1, Slc6a1) [108]. A series of photoswitchable derivatives based on a nipecotic acid scaffold was reported, incorporating azobenzene moieties to confer reversible photoisomerization properties. Biological evaluation revealed that these compounds showed a subtype-selective, moderate to potent inhibitory activity against GAT1, with their efficacy being moderately reversible upon light irradiation. In addition, electrophysiological experiments further demonstrated the ability of the most promising photoswitchable inhibitor, (*R*)-6e (**82**, Figure 12), to modulate neuronal activity in mouse brain slices in an irradiation-dependent manner. As next step, Wanner *et al.* incorporated various azobenzene moieties as *N*-substituents of (*R*)-nipecotic acid [109]. New inhibitors were designed with the aim to achieve potent inhibition in the (*Z*)-form after irradiation, compared to the (*E*)-form, in contrast to the aforementioned (*R*)-6e (**82**), which was more active before irradiation [108]. This may result in a more pronounced difference in activity postirradiation due to the constrained extent to which azobenzenes can transition from the more stable (*E*)- to the less stable (*Z*)-form. This led to the discovery of a novel, potent photoswitchable inhibitor, (*R*)-*m*-20a (**83**, Figure 12), which, unlike previous inhibitors, can be “activated” by photoirradiation, showing a significantly higher pIC₅₀ value in the (*Z*)-form compared to its (*E*)-form.




FIGURE 12 | Molecular structures of photoswitchable inhibitors 82–87 targeting SLCs. Photoreactive azobenzene moieties are highlighted in blue. Original compound names and structures are given in their most active isomer. [Color figure can be viewed at [wileyonlinelibrary.com](https://onlinelibrary.wiley.com)]

In addition to research focused on GABA transporters of the SLC6 family, multiple efforts in photopharmacology of the glutamate transporters have been made. In 2017 the Trauner group successfully developed the first photoswitchable glutamate transporter inhibitor targeting EAAT1-3 (SLC1A1-3) [110]. The compound azo-TFB-TBOA, or ATT (**84**, Figure 12), was synthesized by incorporating an azobenzene moiety into TFB-TBOA. TFB-TBOA is a highly potent inhibitor of glutamate uptake and is widely used for studying glutamate transporter functions in the CNS [218]. ATT displays high activity in the nonirradiated form which was reduced by 14-fold upon reversible photoswitching to the *cis*-form. In addition, another study reported several photochromic azobenzene derivatives of TBOA and TFB-TBOA targeting the archaeal homologue (*Thermococcus kodakarensis*) of glutamate transporters, Glt_{TK} [111]. Upon biological characterization, *p*-MeO-azo-TBOA (**85**, Figure 12) was identified as the most promising photoswitch with a high inhibitory activity in the *trans*-form that drops 3.6-fold when reversibly irradiated.

While the previous photoswitches only gave minor to moderate changes in activity upon photoswitching, more recently, the Trauner group has expanded the focus of their work and developed the first photopharmacological tool for SERT (SLC6A4) by studying the structure–activity relationships of SERT and derivatives of the potent selective inhibitor, escitalopram [112]. Using rational design, an “azostere” was designed and synthesized resulting in azo-escitalopram (**86**, Figure 12), from which the stable *trans*-isomer exhibits minimal activity, serving as an inactive inhibitor. However, upon photoisomerization to the *cis*-isomer, azo-escitalopram demonstrates a striking 43-fold increase in inhibitory potency. This notable distinction between the two isomeric states underlines the potential of azo-escitalopram.

GlyT2 (SLC6A5), another member of the SLC6 family, plays a crucial role in regulating chronic pain, where inhibition of the transporter results in analgesic effects [219, 220]. Reversible inhibition is suggested to prevent toxicity while preserving function; however, the mechanisms and effects of reversible inhibition on glycine neurotransmission remain largely unknown [221]. To further investigate this transporter, Vandenberg et al. developed compound 3 (**87**, Figure 12), a photoswitchable azobenzene derivative of ORG25543 [113]. The parent GlyT2 inhibitor 2, another derivative of ORG25543 with improved toxicity profiles, is a potent inhibitor known to alleviate neuropathic pain in rodent models, featuring a benzyl phenyl ether structure that serves as a starting point for incorporation of an azobenzene [221]. Upon incorporation of the photoswitchable moiety, both isomers of compound 3 act as noncompetitive binders with similar binding activities, though the (*E*)-isomer exhibits twofold lower inhibitory potency value. The activity of both (*Z*)-3 and (*E*)-3 isomers suggests that the GlyT2 binding pocket has conformational flexibility, which should be considered in inhibitor design strategies. Besides optimizing inhibitor design, compound 3 could be valuable for investigating optimal inhibitor levels for maximal analgesic effects and for understanding the mechanisms underlying adverse effects.

Despite the advances in the field of photoswitchable ligands for SLCs, in particular the ability to precisely differentiate and control

active versus inactive conformational state is still in its infancy. In contrast, in GPCR pharmacology, photoswitchable molecules enable the study of receptor signaling pathways by reversibly toggling their active states [222]. Porting these sophisticated strategies to SLCs could unlock unprecedented capabilities for studying their dynamic conformational changes in real-time.

7 | Conclusions and Outlook

This review provides a comprehensive overview of the diverse array of small molecule probes employed in the study of SLCs since 2000, with a particular focus on fluorescent probes, covalent inhibitors, affinity-based probes, bivalent probes, PROTACs and photoswitchable inhibitors. Despite the progress made, there are still considerable challenges that need to be addressed. Future research should focus on expanding the SLC molecular toolbox, enhancing the selectivity and efficacy of these probes, and especially developing chemical probes for those SLCs without any probes reported so far. Among these, PROTACs and photoswitchable probes stand out as particularly compelling avenues for future research. It is worth noting that these approaches are relatively new in the context of SLC studies. Looking ahead, researchers may also consider investigating other chemical probes that have not been traditionally used in the context of SLCs, such as molecular glues for other means of targeted protein degradation such as lysosome targeting chimeras (LYTACs). All future probe developments would also stand to benefit from targeting the less explored SLC families instead of focusing solely on those that are already extensively investigated, such as the SLC6 family. Besides this, the use of structural information (either experimental through X-Ray or CryoEM, or AI-driven through AlphFold) could greatly enhance the capabilities of probe design [223]. Expanding probe diversity and enhancing specificity and efficacy will provide deeper insights into SLC biology and advance therapeutic innovations.

Author Contributions

Conceptualization: Majlen A. Dilweg, Adriaan P. IJzerman, and Daan van der Es. Investigation: Majlen A. Dilweg and Tracie Widjaja. Funding resources and supervision: Adriaan P. IJzerman and Daan van der Es. Writing – original draft: Majlen A. Dilweg and Tracie Widjaja. Writing – reviewing and editing: Majlen A. Dilweg, Adriaan P. IJzerman, and Daan van der Es.

Conflicts of Interest

The authors declare no conflicts of interest.

Data Availability Statement

The authors have nothing to report.

References

1. M. D. Pizzagalli, A. Bensimon, and G. Superti-Furga, “A Guide to Plasma Membrane Solute Carrier Proteins,” *FEBS Journal* 288, no. 9 (2021): 2784–2835, <https://doi.org/10.1111/febs.15531>.
2. E. Ferrada and G. Superti-Furga, “A Structure and Evolutionary-Based Classification of Solute Carriers,” *iScience* 25, no. 10 (2022): 105096, <https://doi.org/10.1016/j.isci.2022.105096>.

3. R. Santos, O. Ursu, A. Gaulton, et al., "A Comprehensive Map of Molecular Drug Targets," *Nature Reviews Drug Discovery* 16, no. 1 (2016): 19–34, <https://doi.org/10.1038/nrd.2016.230>.
4. M. A. Hediger, B. Cl  men  on, R. E. Burrier, and E. A. Bruford, "The ABCs of Membrane Transporters in Health and Disease (SLC Series): Introduction," *Molecular Aspects of Medicine* 34, no. 2–3 (2013): 95–107, <https://doi.org/10.1016/j.mam.2012.12.009>.
5. C. Colas, P. M.-U. Ung, and A. Schlessinger, "SLC Transporters: Structure, Function, and Drug Discovery," *MedChemComm* 7, no. 6 (2016): 1069–1081, <https://doi.org/10.1039/C6MD00005C>.
6. E. Meixner, U. Goldmann, V. Sedlyarov, et al., "A Substrate-Based Ontology for Human Solute Carriers," *Molecular Systems Biology* 16, no. 7 (2020): 1–9, <https://doi.org/10.15252/msb.20209652>.
7. S. Alexander, D. Fabbro, E. Kelly, et al., "The Concise Guide to Pharmacology 2023/24: Transporters," supplement, *British Journal of Pharmacology* 180, no. S2 (2023): 374, <https://doi.org/10.1111/bph.16182>.
8. Y. Zhang, Y. Zhang, K. Sun, Z. Meng, and L. Chen, "The SLC Transporter in Nutrient and Metabolic Sensing, Regulation, and Drug Development," *Journal of Molecular Cell Biology* 11, no. 1 (2019): 1–13, <https://doi.org/10.1093/jmcb/mjy052>.
9. Y. T. K. Nguyen, H. T. T. Ha, T. H. Nguyen, and L. N. Nguyen, "The Role of SLC Transporters for Brain Health and Disease," *Cellular and Molecular Life Sciences* 79, no. 20 (2022), <https://doi.org/10.1007/s00018-021-04074-4>.
10. K. M. Giacomini, S. M. Huang, D. J. Tweedie, et al., "Membrane Transporters in Drug Development," *Nature Reviews Drug Discovery* 9, no. 3 (2010): 215–236, <https://doi.org/10.1038/nrd3028>.
11. S. K. Nigam, "What Do Drug Transporters Really Do?," *Nature Reviews Drug Discovery* 14, no. 1 (2015): 29–44, <https://doi.org/10.1038/nrd4461>.
12. G. Gyimesi and M. A. Hediger, "Transporter-Mediated Drug Delivery," *Molecules* 28, no. 3 (2023): 1151, <https://doi.org/10.3390/molecules28031151>.
13. B. D  ring and E. Petzinger, "Phase 0 and Phase III Transport in Various Organs: Combined Concept of Phases in Xenobiotic Transport and Metabolism," *Drug Metabolism Reviews* 46, no. 3 (2014): 261–282, <https://doi.org/10.3109/03602532.2014.882353>.
14. M. J. Zamek-Gliszczyński, M. E. Taub, P. P. Chothe, et al., "Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance," *Clinical Pharmacology & Therapeutics* 104, no. 5 (2018): 890–899, <https://doi.org/10.1002/cpt.1112>.
15. K. L. R. Brouwer, R. Evers, E. Hayden, et al., "Regulation of Drug Transport Proteins—From Mechanisms to Clinical Impact: A White Paper on Behalf of the International Transporter Consortium," *Clinical Pharmacology & Therapeutics* 112, no. 3 (2022): 461–484, <https://doi.org/10.1002/cpt.2605>.
16. U.S. Food and Drug Administration, In Vitro Drug Interaction Studies—Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry.
17. European Medicines Agency. ICH M12 on Drug Interaction Studies—Scientific guideline.
18. L. Schaller and V. M. Lauschie, "The Genetic Landscape of the Human Solute Carrier (SLC) Transporter Superfamily," *Human Genetics* 138, no. 11–12 (2019): 1359–1377, <https://doi.org/10.1007/s00439-019-02081-x>.
19. T. Schumann, J. K  nig, C. Henke, et al., "Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease," *Pharmacological Reviews* 72, no. 1 (2020): 343–379, <https://doi.org/10.1124/pr.118.015735>.
20. S. El-Gebali, S. Bentz, M. A. Hediger, and P. Anderle, "Solute Carriers (SLCs) in Cancer," *Molecular Aspects of Medicine* 34, no. 2–3 (2013): 719–734, <https://doi.org/10.1016/j.mam.2012.12.007>.
21. A. Lavoro, L. Falzone, B. Tomasello, G. N. Conti, M. Libra, and S. Candido, "In Silico Analysis of the Solute Carrier (SLC) Family in Cancer Indicates a Link Among DNA Methylation, Metabolic Adaptation, Drug Response, and Immune Reactivity," *Frontiers in Pharmacology* 14 (2023): 1191262, <https://doi.org/10.3389/fphar.2023.1191262>.
22. V. Papalazarou and O. D. K. Maddocks, "Supply and Demand: Cellular Nutrient Uptake and Exchange in Cancer," *Molecular Cell* 81, no. 18 (2021): 3731–3748, <https://doi.org/10.1016/j.molcel.2021.08.026>.
23. S. Alam, E. Doherty, P. Ortega-Prieto, J. Arizanova, and L. Fets, "Membrane Transporters in Cell Physiology, Cancer Metabolism and Drug Response," *Disease Models & Mechanisms* 16, no. 11 (2023): dmm050404, <https://doi.org/10.1242/dmm.050404>.
24. Z. C. Nwosu, M. G. Song, M. P. di Magliano, C. A. Lyssiotis, and S. E. Kim, "Nutrient Transporters: Connecting Cancer Metabolism to Therapeutic Opportunities," *Oncogene* 42, no. 10 (2023): 711–724, <https://doi.org/10.1038/s41388-023-02593-x>.
25. N. Thakkar, A. C. Lockhart, and W. Lee, "Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy," *AAPS Journal* 17, no. 3 (2015): 535–545, <https://doi.org/10.1208/s12248-015-9740-x>.
26. R.-A. A. Garib Singh and A. Schlessinger, "Advances and Challenges in Rational Drug Design for SLCs," *Trends in Pharmacological Sciences* 40, no. 10 (2019): 790–800, <https://doi.org/10.1016/j.tips.2019.08.006>.
27. W. W. Wang, L. Gallo, A. Jadhav, R. Hawkins, and C. G. Parker, "The Druggability of Solute Carriers," *Journal of Medicinal Chemistry* 63, no. 8 (2020): 3834–3867, <https://doi.org/10.1021/acs.jmedchem.9b01237>.
28. A. Schlessinger, N. Zatorski, K. Hutchinson, and C. Colas, "Targeting SLC Transporters: Small Molecules as Modulators and Therapeutic Opportunities," *Trends in Biochemical Sciences* 48, no. 9 (2023): 801–814, <https://doi.org/10.1016/j.tibs.2023.05.011>.
29. A. Schlessinger, S. W. Yee, A. Sali, and K. M. Giacomini, "SLC Classification: An Update," *Clinical Pharmacology & Therapeutics* 94, no. 1 (2013): 19–23, <https://doi.org/10.1038/clpt.2013.73>.
30. A. C  sar-Razquin, B. Snijder, T. Frappier-Brinton, et al., "A Call for Systematic Research on Solute Carriers," *Cell* (Cell Press August 1, 2015), 478–487, <https://doi.org/10.1016/j.cell.2015.07.022>.
31. G. Superti-Furga, D. Lackner, T. Wiedmer, et al., "The Resolute Consortium: Unlocking SLC Transporters for Drug Discovery," *Nature Reviews Drug Discovery* 19, no. 7 (2020): 429–430, <https://doi.org/10.1038/d41573-020-00056-6>.
32. T. Wiedmer, A. Ingles-Prieto, U. Goldmann, C. M. Steppan, and G. Superti-Furga, "Accelerating SLC Transporter Research: Streamlining Knowledge and Validated Tools," *Clinical Pharmacology & Therapeutics* 112, no. 3 (2022): 439–442, <https://doi.org/10.1002/cpt.2639>.
33. D. Digles, A. Ingles-Prieto, V. Dvorak, et al., "Advancing Drug Discovery Through Assay Development: A Survey of Tool Compounds Within the Human Solute Carrier Superfamily," *Frontiers in Pharmacology* 15 (2024): 1401599, <https://doi.org/10.3389/fphar.2024.1401599>.
34. A. Casiraghi, A. Bensimon, and G. Superti-Furga, "Recent Developments in Ligands and Chemical Probes Targeting Solute Carrier Transporters," *Current Opinion in Chemical Biology* 62 (2021): 53–63, <https://doi.org/10.1016/j.cbpa.2021.01.012>.
35. M. E. Bunnage, E. L. P. Chekler, and L. H. Jones, "Target Validation Using Chemical Probes," *Nature Chemical Biology* 9, no. 4 (2013): 195–199, <https://doi.org/10.1038/nchembio.1197>.
36. M. P. Licciardello and P. Workman, "The Era of High-Quality Chemical Probes," *RSC Medicinal Chemistry* 13, no. 12 (2022): 1446–1459, <https://doi.org/10.1039/D2MD00291D>.
37. D. Weichert and P. Gmeiner, "Covalent Molecular Probes for Class A G Protein-Coupled Receptors: Advances and Applications," *ACS Chemical Biology* 10, no. 6 (2015): 1376–1386, <https://doi.org/10.1021/acschembio.5b00070>.

38. M. Soave, L. A. Stoddart, C. W. White, et al., "Detection of Genome-Edited and Endogenously Expressed G Protein-Coupled Receptors," *FEBS Journal* 288, no. 8 (2021): 2585–2601, <https://doi.org/10.1111/febs.15729>.
39. Y. Wu, B. Zhang, H. Xu, et al., "The Chronological Evolution of Fluorescent GPCR Probes for Bioimaging," *Coordination Chemistry Reviews* 480 (2023): 215040, <https://doi.org/10.1016/j.ccr.2023.215040>.
40. M. Shimi, V. Sankar, M. K. A. Rahim, et al., "Novel Glycoconjugated Squaraine Dyes for Selective Optical Imaging of Cancer Cells," *Chemical Communications* 53, no. 39 (2017): 5433–5436, <https://doi.org/10.1039/C6CC10282D>.
41. A. Jo, J. Sung, S. Lee, et al., "Near-IR Fluorescent Tracer for Glucose-Uptake Monitoring in Live Cells," *Bioconjugate Chemistry* 29, no. 10 (2018): 3394–3401, <https://doi.org/10.1021/acs.bioconjchem.8b00558>.
42. Y. Cheng, G. Shabir, X. Li, et al., "Development of a Deep-Red Fluorescent Glucose-Conjugated Bioprobe for In Vivo Tumor Targeting," *Chemical Communications* 56, no. 7 (2020): 1070–1073, <https://doi.org/10.1039/C9CC07363A>.
43. Y. Tian, C. Tang, G. Shi, et al., "Novel Fluorescent GLUT1 Inhibitor for Precision Detection and Fluorescence Image-Guided Surgery in Oral Squamous Cell Carcinoma," *International Journal of Cancer* 151, no. 3 (2022): 450–462, <https://doi.org/10.1002/ijc.34049>.
44. J. N. Wilson, L. K. Ladefoged, W. M. Babinchak, and B. Schiøtt, "Binding-Induced Fluorescence of Serotonin Transporter Ligands: A Spectroscopic and Structural Study of 4-(4-(Dimethylamino)Phenyl)-1-Methylpyridinium (AP⁺) and AP⁺ Analogues," *ACS Chemical Neuroscience* 5, no. 4 (2014): 296–304, <https://doi.org/10.1021/cn400230x>.
45. M. R. Post, W.-L. Lee, J. Guo, D. Sames, and D. Sulzer, "Development of a Dual Fluorescent and Magnetic Resonance False Neurotransmitter That Reports Accumulation and Release From Dopaminergic Synaptic Vesicles," *ACS Chemical Neuroscience* 12, no. 24 (2021): 4546–4553, <https://doi.org/10.1021/acschemneuro.1c00580>.
46. M. Lee, N. G. Gubernator, D. Sulzer, and D. Sames, "Development of PH-Responsive Fluorescent False Neurotransmitters," *Journal of the American Chemical Society* 132, no. 26 (2010): 8828–8830, <https://doi.org/10.1021/ja101740k>.
47. W.-L. Lee, X. Westergaard, C. Hwu, et al., "Molecular Design of SERTlight: A Fluorescent Serotonin Probe for Neuronal Labeling in the Brain," *Journal of the American Chemical Society* 146, no. 14 (2024): 9564–9574, <https://doi.org/10.1021/jacs.3c11617>.
48. X. Wang, F. Che, X. Zhang, P. Li, W. Zhang, and B. Tang, "Tracing Superoxide Anion in Serotonergic Neurons of Living Mouse Brains With Depression by Small-Molecule Fluorescence Probes," *Analytical Chemistry* 95, no. 42 (2023): 15614–15620, <https://doi.org/10.1021/acs.analchem.3c02701>.
49. G. A. Camacho-Hernandez, A. Gopinath, A. V. Okorom, H. Khoshbouei, and A. H. Newman, "Development of a Fluorescently Labeled Ligand for Rapid Detection of DAT in Human and Mouse Peripheral Blood Monocytes," *JACS Au* 4, no. 2 (2024): 657–665, <https://doi.org/10.1021/jacsau.3c00719>.
50. Z. Liu, H. Wang, C. Sun, et al., "ZWZ-3, a Fluorescent Probe Targeting Mitochondria for Melanoma Imaging and Therapy," *Frontiers in Pharmacology* 13 (2022): 829684, <https://doi.org/10.3389/fphar.2022.829684>.
51. H. Cho, N.-K. Hong, and Y.-T. Chang, "Novel Fluorescent Strategy for Discriminating T and B Lymphocytes Using Transport System," *Pharmaceutics* 16, no. 3 (2024): 424, <https://doi.org/10.3390/pharmaceutics16030424>.
52. C. Sun, J. Wang, T. Xia, et al., "Mitochondrion-Targeted NIR Therapeutic Agent Suppresses Melanoma by Inducing Apoptosis and Cell Cycle Arrest via E2F/Cyclin/CDK Pathway," *Pharmaceutics* 15, no. 12 (2022): 1589, <https://doi.org/10.3390/ph15121589>.
53. K. Sztandera, M. Gorzkiewicz, E. A. Zizzi, et al., "Cellular Uptake of Rose Bengal Is Mediated by OATP1B1/1B3 Transporters," *Bioelectrochemistry* 152 (2023): 108449, <https://doi.org/10.1016/j.bioelechem.2023.108449>.
54. B. Sui, J. Chen, D. Ge, F. Liang, and H. Wang, "Assembly Characterization of Human Equilibrium Nucleoside Transporter 1 (HENT1) by Inhibitor Probe-Based DSTORM Imaging," *Analytical Chemistry* 95, no. 24 (2023): 9207–9218, <https://doi.org/10.1021/acs.analchem.3c00596>.
55. T. H. V. Huynh, B. Abrahamsen, K. K. Madsen, A. Gonzalez-Franquesa, A. A. Jensen, and L. Bunch, "Design, Synthesis and Pharmacological Characterization of Coumarin-Based Fluorescent Analogs of Excitatory Amino Acid Transporter Subtype 1 Selective Inhibitors, UCPH-101 and UCPH-102," *Bioorganic & Medicinal Chemistry* 20, no. 23 (2012): 6831–6839, <https://doi.org/10.1016/j.bmc.2012.09.049>.
56. R. S. Agnes, B. J. Traugher, and R. F. Muzic, "Development of a Selective Novel Fluorescent Substrate for Sodium-Dependent Transporters," *Life Sciences* 351 (2024): 122847, <https://doi.org/10.1016/j.lfs.2024.122847>.
57. T. M. Ackermann, G. Höfner, and K. T. Wanner, "Screening for New Inhibitors of Glycine Transporter 1 and 2 by Means of MS Binding Assays," *ChemMedChem* 16, no. 19 (2021): 3094–3104, <https://doi.org/10.1002/cmdc.202100408>.
58. M. Daerr, J. Pabel, G. Höfner, P. Mayer, and K. T. Wanner, "Synthesis and Biological Evaluation of Fluorescent GAT-Ligands Based on Meso-Substituted BODIPY Dyes," *Medicinal Chemistry Research* 29, no. 2 (2020): 301–327, <https://doi.org/10.1007/s00044-019-02483-6>.
59. Q. Zhu, H. Komori, R. Imamura, and I. Tamai, "A Novel Fluorescence-Based Method to Evaluate Ileal Apical Sodium-Dependent Bile Acid Transporter ASBT," *Journal of Pharmaceutical Sciences* 110, no. 3 (2021): 1392–1400, <https://doi.org/10.1016/j.xphs.2020.11.030>.
60. T. De Bruyn, W. Sempels, J. Snoeys, et al., "Confocal Imaging With a Fluorescent Bile Acid Analogue Closely Mimicking Hepatic Taur-ocholate Disposition," *Journal of Pharmaceutical Sciences* 103, no. 6 (2014): 1872–1881, <https://doi.org/10.1002/jps.23933>.
61. D. Bednarczyk, E. A. Mash, B. R. Aavula, and S. H. Wright, "NBD-TMA: A Novel Fluorescent Substrate of the Peritubular Organic Cation Transporter of Renal Proximal Tubules," *Pflügers Archiv—European Journal of Physiology* 440, no. 1 (2000): 184–192, <https://doi.org/10.1007/s004240051038>.
62. B. Reddy Aavula, M. Ahad Ali, E. A. Mash, D. Bednarczyk, and S. H. Wright, "Synthesis and Fluorescence of N,N,N-Trimethyl-2-[methyl(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl) Amino]Ethanaminium Iodide, a pH-Insensitive Reporter of Organic Cation Transport," *Synthetic communications* 36, no. 6 (2006): 701–705, <https://doi.org/10.1080/00397910500446597>.
63. H. Cho, H.-Y. Kwon, Y. Kim, et al., "Development of a Mature B Lymphocyte Probe Through Gating-Oriented Live-Cell Distinction (GOLD) and Selective Imaging of Topical Spleen," *JACS Au* 4, no. 4 (2024): 1450–1457, <https://doi.org/10.1021/jacsau.4c00001>.
64. H. Cho, H.-Y. Kwon, S. H. Lee, H.-G. Lee, N.-Y. Kang, and Y.-T. Chang, "Development of a Fluorescent Probe for M2 Macrophages via Gating-Oriented Live-Cell Distinction," *Journal of the American Chemical Society* 145, no. 5 (2023): 2951–2957, <https://doi.org/10.1021/jacs.2c11393>.
65. A. Claudio-Montero, I. Pinilla-Macua, P. Fernández-Calotti, et al., "Fluorescent Nucleoside Derivatives as a Tool for the Detection of Concentrative Nucleoside Transporter Activity Using Confocal Microscopy and Flow Cytometry," *Molecular Pharmaceutics* 12, no. 6 (2015): 2158–2166, <https://doi.org/10.1021/acs.molpharmaceut.5b00142>.
66. K. Kayano, T. Tsutsumi, Y. Murata, et al., "Epoxide Ring-Opening Reactions for Abundant Production of Mugenic Acids and Nicotianamine Probes," *Angewandte Chemie International Edition* 63, no. 20 (2024): e202401411, <https://doi.org/10.1002/anie.202401411>.

67. M. Hashimoto, J. Yang, Y. Hatanaka, Y. Sadakane, K. Nakagomi, and G. D. Holman, "Improvement in the Properties of 3-Phenyl-3-Trifluoromethylthiohydrazine Based Photoreactive Bis-Glucose Probes for GLUT4 Following Substitution on the Phenyl Ring," *Chemical and Pharmaceutical Bulletin* 50, no. 7 (2002): 1004–1006, <https://doi.org/10.1248/cpb.50.1004>.
68. N. K. Tyagi and R. K. H. Kinne, "Synthesis of Photoaffinity Probes [2'-iodo-4'-(3"-trifluoromethylthiohydrazinyl)phenoxy]-d-glucopyranoside and [(4'-benzoyl)phenoxy]-d-glucopyranoside for the Identification of Sugar-Binding and Phlorizin-Binding Sites in the Sodium/D-Glucose Cotransporter Protein," *Analytical Biochemistry* 323, no. 1 (2003): 74–83, <https://doi.org/10.1016/j.ab.2003.08.004>.
69. M. M. Raja, H. Kipp, and R. K. H. Kinne, "C-Terminus Loop 13 of Na⁺ Glucose Cotransporter SGLT1 Contains a Binding Site for Alkyl Glucosides," *Biochemistry* 43, no. 34 (2004): 10944–10951, <https://doi.org/10.1021/bi049106n>.
70. M. Leuenberger, A. Ritler, A. Simonin, M. A. Hediger, and M. Lochner, "Concise Asymmetric Synthesis and Pharmacological Characterization of all Stereoisomers of Glutamate Transporter Inhibitor TFB-TBOA and Synthesis of EAAT Photoaffinity Probes," *ACS Chemical Neuroscience* 7, no. 5 (2016): 534–539, <https://doi.org/10.1021/acscchemneuro.5b00311>.
71. M.-F. Zou, T. Kopajtic, J. L. Katz, S. Wirtz, J. B. Justice, and A. H. Newman, "Novel Tropane-Based Irreversible Ligands for the Dopamine Transporter," *Journal of Medicinal Chemistry* 44, no. 25 (2001): 4453–4461, <https://doi.org/10.1021/jm0101904>.
72. M.-F. Zou, T. Kopajtic, J. L. Katz, and A. H. Newman, "Structure–Activity Relationship Comparison of (S)-2 β -Substituted 3 α -(Bis[4-fluorophenyl]methoxy)tropanes and (R)-2 β -Substituted 3 β -(3,4-Dichlorophenyl)tropanes at the Dopamine Transporter," *Journal of Medicinal Chemistry* 46, no. 14 (2003): 2908–2916, <https://doi.org/10.1021/jm0300375>.
73. J. Cao, J. R. Lever, T. Kopajtic, et al., "Novel Azido and Isothiocyanato Analogues of [3-(4-Phenylalkyl)piperazin-1-yl]PropylBis(4-Fluorophenyl)Amines as Potential Irreversible Ligands for the Dopamine Transporter," *Journal of Medicinal Chemistry* 47, no. 25 (2004): 6128–6136, <https://doi.org/10.1021/jm049670w>.
74. V. Murthy, H. M. L. Davies, S. J. Hedley, and S. R. Childers, "Irreversible Binding of a Novel Phenylisothiocyanate Tropane Analog to Monoamine Transporters in Rat Brain," *Biochemical Pharmacology* 74, no. 2 (2007): 336–344, <https://doi.org/10.1016/j.bcp.2007.04.019>.
75. P. C. Meltzer, S. Liu, H. S. Blanchette, P. Blundell, and B. K. Madras, "Design and Synthesis of an Irreversible Dopamine-Sparing Cocaine Antagonist," *Bioorganic & Medicinal Chemistry* 10, no. 11 (2002): 3583–3591, [https://doi.org/10.1016/S0968-0896\(02\)00244-4](https://doi.org/10.1016/S0968-0896(02)00244-4).
76. F. Oppedisano, M. Catto, P. A. Koutentis, et al., "Inactivation of the Glutamine/Amino Acid Transporter ASCT2 by 1,2,3-Dithiazoles: Proteoliposomes as a Tool to Gain Insights in the Molecular Mechanism of Action and of Antitumor Activity," *Toxicology and Applied Pharmacology* 265, no. 1 (2012): 93–102, <https://doi.org/10.1016/j.taap.2012.09.011>.
77. P. M. González, N. Hussainzada, P. W. Swaan, A. D. MacKerell, and J. E. Polli, "Putative Irreversible Inhibitors of the Human Sodium-Dependent Bile Acid Transporter (HASBT; SLC10A2) Support the Role of Transmembrane Domain 7 in Substrate Binding/Translocation," *Pharmaceutical Research* 29, no. 7 (2012): 1821–1831, <https://doi.org/10.1007/s11095-012-0706-8>.
78. Y. Takashima, K. Ishikawa, R. Miyawaki, et al., "Modulatory Effect of Theaflavins on Apical Sodium-Dependent Bile Acid Transporter (ASBT) Activity," *Journal of Agricultural and Food Chemistry* 69, no. 33 (2021): 9585–9596, <https://doi.org/10.1021/acs.jafc.1c03483>.
79. A. Aoyama, M. Murai, N. Ichimaru, S. Aburaya, W. Aoki, and H. Miyoshi, "Epoxycyclohexenedione-Type Compounds Make Up a New Class of Inhibitors of the Bovine Mitochondrial ADP Carrier," *Biochemistry* 57, no. 6 (2018): 1031–1044, <https://doi.org/10.1021/acs.biochem.7b01119>.
80. Y. Yamashita, E. V. Vinogradova, X. Zhang, R. M. Suci, and B. F. Cravatt, "A Chemical Proteomic Probe for the Mitochondrial Pyruvate Carrier Complex," *Angewandte Chemie International Edition* 59, no. 10 (2020): 3896–3899, <https://doi.org/10.1002/anie.201914391>.
81. A. H. Newman, J. H. Cha, J. Cao, et al., "Design and Synthesis of a Novel Photoaffinity Ligand for the Dopamine and Serotonin Transporters Based on 2 β -Carbomethoxy-3 β -Biphenyltropane," *Journal of Medicinal Chemistry* 49, no. 22 (2006): 6621–6625, <https://doi.org/10.1021/jm0603973>.
82. D. J. Lapinsky, S. Aggarwal, Y. Huang, et al., "A Novel Photoaffinity Ligand for the Dopamine Transporter Based on Pyrovalerone," *Bioorganic & Medicinal Chemistry* 17, no. 11 (2009): 3770–3774, <https://doi.org/10.1016/j.bmc.2009.04.057>.
83. D. J. Lapinsky, S. Aggarwal, T. L. Nolan, et al., "($\pm$)-2-(N-Tert-Butylamino)-3'-[¹²⁵I]-Iodo-4'-Azidopropiophenone: A Dopamine Transporter and Nicotinic Acetylcholine Receptor Photoaffinity Ligand Based on Bupropion (Wellbutrin, Zyban)," *Bioorganic & Medicinal Chemistry Letters* 22, no. 1 (2012): 523–526, <https://doi.org/10.1016/j.bmcl.2011.10.086>.
84. M. K. Sievert, A. R. Hajipour, and A. E. Ruoho, "Specific Derivatization of the Vesicle Monoamine Transporter With Novel Carrier-Free Radioiodinated Reserpine and Tetrabenazine Photoaffinity Labels," *Analytical Biochemistry* 367, no. 1 (2007): 68–78, <https://doi.org/10.1016/j.ab.2007.04.046>.
85. C. M. Murray, R. Hutchinson, J. R. Bantick, et al., "Monocarboxylate Transporter MCT1 Is a Target for Immunosuppression," *Nature Chemical Biology* 1, no. 7 (2005): 371–376, <https://doi.org/10.1038/nchembio744>.
86. J. K. Addo and J. K. Buolamwini, "Design, Synthesis, and Evaluation of 5'-S-Aminoethyl-N⁶-Azidobenzyl-5'-Thioadenosine Biotin Conjugate: A Bifunctional Photoaffinity Probe for the Es Nucleoside Transporter," *Bioconjugate Chemistry* 15, no. 3 (2004): 536–540, <https://doi.org/10.1021/bc034165j>.
87. T. Kirmeier, R. Gopalakrishnan, V. Gormanns, et al., "Azidobupramine, an Antidepressant-Derived Bifunctional Neurotransmitter Transporter Ligand Allowing Covalent Labeling and Attachment of Fluorophores," *PLoS One* 11, no. 2 (2016): e0148608, <https://doi.org/10.1371/journal.pone.0148608>.
88. N. Yarravarapu, L. Geffert, C. K. Surratt, M. Cascio, and D. J. Lapinsky, "Clickable Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-Citalopram," *Bioorganic & Medicinal Chemistry Letters* 28, no. 21 (2018): 3431–3435, <https://doi.org/10.1016/j.bmcl.2018.09.029>.
89. E. Nolin, S. Gans, L. Llamas, et al., "Discovery of a ZIP7 Inhibitor From a Notch Pathway Screen," *Nature Chemical Biology* 15, no. 2 (2019): 179–188, <https://doi.org/10.1038/s41589-018-0200-7>.
90. K. Ohgane, F. Karaki, K. Dodo, and Y. Hashimoto, "Discovery of Oxysterol-Derived Pharmacological Chaperones for NPC1: Implication for the Existence of Second Sterol-Binding Site," *Chemistry & Biology* 20, no. 3 (2013): 391–402, <https://doi.org/10.1016/j.chembiol.2013.02.009>.
91. R. Shioi, F. Karaki, H. Yoshioka, et al., "Image-Based Screen Capturing Misfolding Status of Niemann-Pick Type C1 Identifies Potential Candidates for Chaperone Drugs," *PLoS One* 15, no. 12 (2020): e0243746, <https://doi.org/10.1371/journal.pone.0243746>.
92. A. Kawatkar, R. A. Clark, L. Hopcroft, et al., "Chemical Biology Approaches Confirm MCT4 as the Therapeutic Target of a Cellular Optimized Hit," *ACS Chemical Biology* 18, no. 2 (2023): 296–303, <https://doi.org/10.1021/acscmbio.2c00666>.
93. F. W. Goldberg, J. G. Kettle, G. M. Lamont, et al., "Discovery of Clinical Candidate AZD0095, a Selective Inhibitor of Monocarboxylate Transporter 4 (MCT4) for Oncology," *Journal of Medicinal Chemistry* 66, no. 1 (2023): 384–397, <https://doi.org/10.1021/acs.jmedchem.2c01342>.

94. V. Dvorak, A. Casiraghi, C. Colas, et al., "Paralog-Dependent Isonic Cell Assay Cascade Generates Highly Selective SLC16A3 Inhibitors," *Cell Chemical Biology* 30, no. 8 (2023): 953–964.e9, <https://doi.org/10.1016/j.chembiol.2023.06.029>.
95. T.-Y. Chiu, D. C. Lazar, W. W. Wang, et al., "Chemoproteomic Development of SLC15A4 Inhibitors With Anti-Inflammatory Activity," *Nature Chemical Biology* 20, no. 8 (2024): 1000–1011, <https://doi.org/10.1038/s41589-023-01527-8>.
96. C. G. Parker, C. A. Kuttruff, A. Galmozzi, et al., "Chemical Proteomics Identifies SLC25A20 as a Functional Target of the Ingenol Class of Actinic Keratosis Drugs," *ACS Central Science* 3, no. 12 (2017): 1276–1285, <https://doi.org/10.1021/acscentsci.7b00420>.
97. J. R. Lever, M.-F. Zou, M. L. Parnas, et al., "Radioiodinated Azide and Isothiocyanate Derivatives of Cocaine for Irreversible Labeling of Dopamine Transporters: Synthesis and Covalent Binding Studies," *Bioconjugate Chemistry* 16, no. 3 (2005): 644–649, <https://doi.org/10.1021/bc0497214>.
98. A. Moriyama, N. Katagiri, S. Nishimura, N. Takahashi, and H. Kakeya, "In Vivo Linking of Membrane Lipids and the Anion Transporter Band 3 With Thiourea-Modified Amphiphilic Lipid Probes," *Scientific Reports* 5, no. 1 (2015): 17427, <https://doi.org/10.1038/srep17427>.
99. S. Nielsen, C. M. Pedersen, S. G. Hansen, et al., "An Extended Study of Dimeric Phenyl Tropanes," *Bioorganic & Medicinal Chemistry* 17, no. 14 (2009): 4900–4909, <https://doi.org/10.1016/j.bmc.2009.06.007>.
100. P. C. Meltzer, O. Kryatova, D.-P. Pham-Huu, P. Donovan, and A. Janowsky, "The Synthesis of Bivalent 2 β -Carbomethoxy-3 β -(3,4-Dichlorophenyl)-8-Heterobicyclo[3.2.1]Octanes as Probes for Proximal Binding Sites on the Dopamine and Serotonin Transporters," *Bioorganic & Medicinal Chemistry* 16, no. 4 (2008): 1832–1841, <https://doi.org/10.1016/j.bmc.2007.11.009>.
101. S. A. Bright, A. Brinkø, M. T. Larsen, S. Sinning, D. C. Williams, and H. H. Jensen, "Basic N-Interlinked Imipramines Show Apoptotic Activity Against Malignant Cells Including Burkitt's Lymphoma," *Bioorganic & Medicinal Chemistry Letters* 23, no. 5 (2013): 1220–1224, <https://doi.org/10.1016/j.bmcl.2013.01.020>.
102. A. K. Banala, P. Zhang, P. Plenge, et al., "Design and Synthesis of 1-(3-(Dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile (Citalopram) Analogues as Novel Probes for the Serotonin Transporter S1 and S2 Binding Sites," *Journal of Medicinal Chemistry* 56, no. 23 (2013): 9709–9724, <https://doi.org/10.1021/jm4014136>.
103. J. Andersen, L. K. Ladefoged, T. N. B. Kristensen, et al., "Interrogating the Molecular Basis for Substrate Recognition in Serotonin and Dopamine Transporters With High-Affinity Substrate-Based Bivalent Ligands," *ACS Chemical Neuroscience* 7, no. 10 (2016): 1406–1417, <https://doi.org/10.1021/acscchemneuro.6b00164>.
104. K. C. Schmitt, S. Mamidyalala, S. Biswas, A. K. Dutta, and M. E. A. Reith, "Bivalent Phenethylamines as Novel Dopamine Transporter Inhibitors: Evidence for Multiple Substrate-Binding Sites in a Single Transporter," *Journal of Neurochemistry* 112, no. 6 (2010): 1605–1618, <https://doi.org/10.1111/j.1471-4159.2010.06583.x>.
105. H. Pessoa-Mahana, C. González-Lira, A. Fierro, et al., "Synthesis, Docking and Pharmacological Evaluation of Novel Homo- and Hetero-Bis 3-Piperazinylpropylindole Derivatives at SERT and 5-HT_{1A} Receptor," *Bioorganic & Medicinal Chemistry* 21, no. 24 (2013): 7604–7611, <https://doi.org/10.1016/j.bmc.2013.10.036>.
106. I. Ruchala, U. M. Battisti, V. T. Nguyen, R. Y.-T. Chen, R. A. Glennon, and J. M. Eltit, "Functional Characterization of N-Octyl 4-Methylamphetamine Variants and Related Bivalent Compounds at the Dopamine and Serotonin Transporters Using Ca²⁺ Channels as Sensors," *Toxicology and Applied Pharmacology* 419 (2021): 115513, <https://doi.org/10.1016/j.taap.2021.115513>.
107. A. Bensimon, M. D. Pizzagalli, F. Kartnig, et al., "Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis," *Cell Chemical Biology* 27, no. 6 (2020): 728–739.e9, <https://doi.org/10.1016/j.chembiol.2020.04.003>.
108. G. Quandt, G. Höfner, J. Pabel, J. Dine, M. Eder, and K. T. Wanner, "First Photoswitchable Neurotransmitter Transporter Inhibitor: Light-Induced Control of γ -Aminobutyric Acid Transporter 1 (GAT1) Activity in Mouse Brain," *Journal of Medicinal Chemistry* 57, no. 15 (2014): 6809–6821, <https://doi.org/10.1021/jm5008566>.
109. T. Lutz, T. Wein, G. Höfner, et al., "Development of New Photoswitchable Azobenzene Based γ -Aminobutyric Acid (GABA) Uptake Inhibitors With Distinctly Enhanced Potency Upon Photoactivation," *Journal of Medicinal Chemistry* 61, no. 14 (2018): 6211–6235, <https://doi.org/10.1021/acs.jmedchem.8b00629>.
110. B. Cheng, D. Shchepakina, M. P. Kavanaugh, and D. Trauner, "Photoswitchable Inhibitor of a Glutamate Transporter," *ACS Chemical Neuroscience* 8, no. 8 (2017): 1668–1672, <https://doi.org/10.1021/acscchemneuro.7b00072>.
111. M. W. H. Hoorens, H. Fu, R. H. Duurkens, et al., "Glutamate Transporter Inhibitors With Photo-Controlled Activity," *Advanced Therapeutics (Weinh)* 1, no. 2 (2018): 1–7, <https://doi.org/10.1002/adtp.201800028>.
112. B. Cheng, J. Morstein, L. K. Ladefoged, et al., "A Photoswitchable Inhibitor of the Human Serotonin Transporter," *ACS Chemical Neuroscience* 11, no. 9 (2020): 1231–1237, <https://doi.org/10.1021/acscchemneuro.9b00521>.
113. S. N. Mostyn, S. Sarker, P. Muthuraman, et al., "Photoswitchable ORG25543 Congener Enables Optical Control of Glycine Transporter 2," *ACS Chemical Neuroscience* 11, no. 9 (2020): 1250–1258, <https://doi.org/10.1021/acscchemneuro.9b00655>.
114. R. Sridharan, J. Zuber, S. M. Connelly, E. Mathew, and M. E. Dumont, "Fluorescent Approaches for Understanding Interactions of Ligands With G Protein Coupled Receptors," *Biochimica et Biophysica Acta (BBA)—Biomembranes* 1838, no. 1 (2014): 15–33, <https://doi.org/10.1016/j.bbame.2013.09.005>.
115. S. Munan, Y.-T. Chang, and A. Samanta, "Chronological Development of Functional Fluorophores for Bio-Imaging," *Chemical Communications* 60, no. 5 (2024): 501–521, <https://doi.org/10.1039/D3CC04895K>.
116. J. C. McGrath, S. Arribas, and C. J. Daly, "Fluorescent Ligands for the Study of Receptors," *Trends in Pharmacological Sciences* 17, no. 11 (1996): 393–399, [https://doi.org/10.1016/S0165-6147\(96\)40004-9](https://doi.org/10.1016/S0165-6147(96)40004-9).
117. Q. Zheng and L. D. Lavis, "Development of Photostable Fluorophores for Molecular Imaging," *Current Opinion in Chemical Biology* 39 (2017): 32–38, <https://doi.org/10.1016/J.CBPA.2017.04.017>.
118. M. Soave, S. J. Bridson, S. J. Hill, and L. A. Stoddart, "Fluorescent Ligands: Bringing Light to Emerging GPCR Paradigms," *British Journal of Pharmacology* 177, no. 5 (2020): 978–991, <https://doi.org/10.1111/bph.14953>.
119. I. Böhme and A. G. Beck-Sickinger, "Illuminating the Life of GPCRs," *Cell Communication and Signaling* 7, no. 16 (2009), <https://doi.org/10.1186/1478-811X-7-16>.
120. R. A. Petazzi, A. K. Aji, and S. Chiantia, "Fluorescence Microscopy Methods for the Study of Protein Oligomerization," in *Oligomerization in Health and Disease: From Enzymes to G Protein-Coupled Receptors*, Vol. 169, eds. J. Giraldo and F. Ciruela (Academic Press, 2020), 1–41, <https://doi.org/10.1016/bs.pmbts.2019.12.001>.
121. J. B. Grimm and L. D. Lavis, "Caveat Fluorophore: An Insiders' Guide to Small-Molecule Fluorescent Labels," *Nature Methods* 19, no. 2 (2022): 149–158, <https://doi.org/10.1038/s41592-021-01338-6>.
122. Z. Zeng, S. S. Liew, X. Wei, and K. Pu, "Hemicyanine-Based Near-Infrared Activatable Probes for Imaging and Diagnosis of Diseases," *Angewandte Chemie International Edition* 60, no. 51 (2021): 26454–26475, <https://doi.org/10.1002/anie.202107877>.

123. H. Li, H. Kim, F. Xu, et al., "Activity-Based NIR Fluorescent Probes Based on the Versatile Hemicyanine Scaffold: Design Strategy, Bio-medical Applications, and Outlook," *Chemical Society Reviews* 51, no. 5 (2022): 1795–1835, <https://doi.org/10.1039/D1CS00307K>.
124. L. Lu, N. Chen, B. Yuan, et al., "Illuminating the Invisible: Advancing Bio-Imaging and Diagnosis With Modified Near-Infrared Fluorescents," *Applied Materials Today* 38 (2024): 102210, <https://doi.org/10.1016/j.apmt.2024.102210>.
125. Y.-K. Choi, J.-J. Kim, and Y.-T. Chang, "Holding-Oriented Versus Gating-Oriented Live-Cell Distinction: Highlighting the Role of Transporters in Cell Imaging Probe Development," *Accounts of Chemical Research* 52, no. 11 (2019): 3097–3107, <https://doi.org/10.1021/acs.accounts.9b00253>.
126. X. Liu and Y.-T. Chang, "Fluorescent Probe Strategy for Live Cell Distinction," *Chemical Society Reviews* 51, no. 5 (2022): 1573–1591, <https://doi.org/10.1039/D1CS00388G>.
127. L. M. Ciaramicoli and Y.-T. Chang, "Chemical Probes Based on GOLD: The Discovery and Elucidation of Mechanism," *Bulletin of the Korean Chemical Society* 44, no. 8 (2023): 679–692, <https://doi.org/10.1002/bkcs.12713>.
128. W. H. Kim, J. Lee, D.-W. Jung, and D. R. Williams, "Visualizing Sweetness: Increasingly Diverse Applications for Fluorescent-Tagged Glucose Bioprobes and Their Recent Structural Modifications," *Sensors* 12, no. 4 (2012): 5005–5027, <https://doi.org/10.3390/s120405005>.
129. M. Tanasova and J. R. Fedie, "Molecular Tools for Facilitative Carbohydrate Transporters (Gluts)," *ChemBioChem* 18, no. 18 (2017): 1774–1788, <https://doi.org/10.1002/cbic.201700221>.
130. M. Tanasova, V. V. Begoyan, and L. J. Weselinski, "Targeting Sugar Uptake and Metabolism for Cancer Identification and Therapy: An Overview," *Current Topics in Medicinal Chemistry* 18, no. 6 (2018): 467–483, <https://doi.org/10.2174/1568026618666180523110837>.
131. L. M. Ciaramicoli and Y. T. Chang, "Chemical Probes Based On-GOLD: The Discovery and Elucidation of Mechanism," *Bulletin of the Korean Chemical Society* 44, no. 8 (2023): 679–692, <https://doi.org/10.1002/bkcs.12713>.
132. H. Xu, X. Liu, J. Yang, et al., "Cyanine-Based 1-Amino-1-Deoxyglucose as Fluorescent Probes for Glucose Transporter Mediated Bioimaging," *Biochemical and Biophysical Research Communications* 474, no. 2 (2016): 240–246, <https://doi.org/10.1016/j.bbrc.2016.03.133>.
133. X. Liu, S. Liu, X. Liu, et al., "Fluorescent 6-Amino-6-Deoxyglycoconjugates for Glucose Transporter Mediated Bioimaging," *Biochemical and Biophysical Research Communications* 480, no. 3 (2016): 341–347, <https://doi.org/10.1016/j.bbrc.2016.10.045>.
134. Q. Wu, M. Cai, J. Gao, et al., "Developing Substrate-Based Small Molecule Fluorescent Probes for Super-Resolution Fluorescent Imaging of Various Membrane Transporters," *Nanoscale Horizons* 5, no. 3 (2020): 523–529, <https://doi.org/10.1039/C9NH00596J>.
135. S. Chen, Y. Fang, Q. Zhu, W. Zhang, X. Zhang, and W. Lu, "NIR Fluorescent DCPO Glucose Analogues and Their Application in Cancer Cell Imaging," *RSC Advances* 6, no. 85 (2016): 81894–81901, <https://doi.org/10.1039/C6RA18613K>.
136. Y. Fang, W. Zhang, M. Zhu, et al., "Characterization of a Near-Infrared Fluorescent DCPO-Tagged Glucose Analogue for Cancer Cell Imaging," *Journal of Photochemistry and Photobiology, B: Biology* 166 (2017): 264–271, <https://doi.org/10.1016/j.jphotobiol.2016.11.021>.
137. G. A. Camacho-Hernandez, K. Jahan, and A. H. Newman, "Illuminating the Monoamine Transporters: Fluorescently Labelled Ligands to Study Dopamine, Serotonin and Norepinephrine Transporters," *Basic & Clinical Pharmacology & Toxicology* 133, no. 5 (2023): 473–484, <https://doi.org/10.1111/bcpt.13827>.
138. M. R. Post and D. Sulzer, "The Chemical Tools for Imaging Dopamine Release," *Cell Chemical Biology* 28, no. 6 (2021): 748–764, <https://doi.org/10.1016/j.chembiol.2021.04.005>.
139. O. Fardel, M. Le Vee, E. Jouan, C. Denizot, and Y. Parmentier, "Nature and Uses of Fluorescent Dyes for Drug Transporter Studies," *Expert Opinion on Drug Metabolism & Toxicology* 11, no. 8 (2015): 1233–1251, <https://doi.org/10.1517/17425255.2015.1053462>.
140. C. Özvegy-Laczka, O. Ungvári, and É. Bakos, "Fluorescence-Based Methods for Studying Activity and Drug-Drug Interactions of Hepatic Solute Carrier and ATP Binding Cassette Proteins Involved in ADME-Tox," *Biochemical Pharmacology* 209 (2023): 115448, <https://doi.org/10.1016/j.bcp.2023.115448>.
141. C. Zhang, L. Long, and C. Shi, "Mitochondria-Targeting IR-780 Dye and Its Derivatives: Synthesis, Mechanisms of Action, and Theranostic Applications," *Advanced Therapeutics (Weinh)* 1, no. 7 (2018): 1–22, <https://doi.org/10.1002/adtp.201800069>.
142. S. De Cesco, J. Kurian, C. Dufresne, A. K. Mittermaier, and N. Moitessier, "Covalent Inhibitors Design and Discovery," *European Journal of Medicinal Chemistry* 138 (2017): 96–114, <https://doi.org/10.1016/j.ejmech.2017.06.019>.
143. T. A. Baillie, "Targeted Covalent Inhibitors for Drug Design," *Angewandte Chemie International Edition* 55, no. 43 (2016): 13408–13421, <https://doi.org/10.1002/anie.201601091>.
144. L. Boike, N. J. Henning, and D. K. Nomura, "Advances in Covalent Drug Discovery," *Nature Reviews Drug Discovery* 21, no. 12 (2022): 881–898, <https://doi.org/10.1038/s41573-022-00542-z>.
145. L. Zheng, Y. Li, D. Wu, et al., "Development of Covalent Inhibitors: Principle, Design, and Application in Cancer," *MedComm—Oncology* 2, no. 4 (2023): e56, <https://doi.org/10.1002/MOG2.56>.
146. J. C. Byrd, R. R. Furman, S. E. Coutre, et al., "Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia," *New England Journal of Medicine* 369, no. 1 (2013): 32–42, <https://doi.org/10.1056/NEJMoa1215637>.
147. T. S. Mok, Y.-L. Wu, M.-J. Ahn, et al., "Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer," *New England Journal of Medicine* 376, no. 7 (2017): 629–640, <https://doi.org/10.1056/NEJMoa1612674>.
148. D. R. Owen, C. Allerton, A. S. Anderson, et al., "An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19," *Science (New York, N.Y.)* 374, no. 6575 (2021): 1586–1593, <https://doi.org/10.1126/science.aba4784>.
149. M. Gehring and S. A. Laufer, "Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: Applications in Medicinal Chemistry and Chemical Biology," *Journal of Medicinal Chemistry* 62, no. 12 (2019): 5673–5724, <https://doi.org/10.1021/acs.jmedchem.8b01153>.
150. S.-S. Ge, B. Chen, Y.-Y. Wu, et al., "Current Advances of Carbene-Mediated Photoaffinity Labeling in Medicinal Chemistry," *RSC Advances* 8, no. 51 (2018): 29428–29454, <https://doi.org/10.1039/C8RA03538E>.
151. L. Hillebrand, X. J. Liang, R. A. M. Serafim, and M. Gehring, "Emerging and Re-Emerging Warheads for Targeted Covalent Inhibitors: An Update," *Journal of Medicinal Chemistry* 67, no. 10 (2024): 7668–7758, <https://doi.org/10.1021/acs.jmedchem.3c01825>.
152. J. Singh, R. C. Petter, T. A. Baillie, and A. Whitty, "The Resurgence of Covalent Drugs," *Nature Reviews Drug Discovery* 10, no. 4 (2011): 307–317, <https://doi.org/10.1038/nrd3410>.
153. A. Tuley and W. Fast, "The Taxonomy of Covalent Inhibitors," *Biochemistry* 57, no. 24 (2018): 3326–3337, <https://doi.org/10.1021/acs.biochem.8b00315>.
154. S. A. Fleming, "Chemical Reagents in Photoaffinity Labeling," *Tetrahedron* 51, no. 46 (1995): 12479–12520, [https://doi.org/10.1016/0040-4020\(95\)00598-3](https://doi.org/10.1016/0040-4020(95)00598-3).
155. E. Karaj, S. H. Sindi, and L. M. Viranga Tillekeratne, "Photoaffinity Labeling and Bioorthogonal Ligation: Two Critical Tools for Designing 'Fish Hooks' to Scout for Target Proteins," *Bioorganic & Medicinal Chemistry* 62 (2022): 116721, <https://doi.org/10.1016/j.bmc.2022.116721>.

156. W. Kramer, U. Bickel, H. P. Buscher, W. Gerok, and G. Kurz, "Bile-Salt-Binding Polypeptides in Plasma Membranes of Hepatocytes Revealed by Photoaffinity Labelling," *European Journal of Biochemistry* 129, no. 1 (1982): 13–24, <https://doi.org/10.1111/J.1432-1033.1982.TB07015.X>.
157. G. Dormán, H. Nakamura, A. Pulsipher, and G. D. Prestwich, "The Life of Pi Star: Exploring the Exciting and Forbidden Worlds of the Benzophenone Photophore," *Chemical Reviews* 116, no. 24 (2016): 15284–15398, <https://doi.org/10.1021/acs.chemrev.6b00342>.
158. R. A. Vaughan, "Photoaffinity-Labeled Ligand Binding Domains on Dopamine Transporters Identified by Peptide Mapping," *Molecular Pharmacology* 47, no. 5 (1995): 956–964.
159. L. Napolitano, M. Scalise, M. Koyioni, et al., "Potent Inhibitors of Human LAT1 (SLC7A5) Transporter Based on Dithiazole and Dithiazine Compounds for Development of Anticancer Drugs," *Biochemical Pharmacology* 143 (2017): 39–52, <https://doi.org/10.1016/j.bcp.2017.07.006>.
160. W. Kramer, F. Girbig, H. Glombik, D. Corsiero, S. Stengelin, and C. Weyland, "Identification of a Ligand-Binding Site in the Na⁺/Bile Acid Cotransporting Protein From Rabbit Ileum," *Journal of Biological Chemistry* 276, no. 38 (2001): 36020–36027, <https://doi.org/10.1074/jbc.M104665200>.
161. E. O. J. Porta and P. G. Steel, "Activity-Based Protein Profiling: A Graphical Review," *Current Research in Pharmacology and Drug Discovery* 5 (2023): 100164, <https://doi.org/10.1016/j.crphar.2023.100164>.
162. P. P. Geurink, L. M. Prely, G. A. van der Marel, R. Bischoff, and H. S. Overkleef, "Photoaffinity Labeling in Activity-Based Protein Profiling," in *Activity-Based Protein Profiling*, eds. S. A. Sieber (Springer Berlin Heidelberg, 2011), 85–113, https://doi.org/10.1007/128_2011_286.
163. N. R. Burton, P. Kim, and K. M. Backus, "Photoaffinity Labelling Strategies for Mapping the Small Molecule–Protein Interactome," *Organic & Biomolecular Chemistry* 19, no. 36 (2021): 7792–7809, <https://doi.org/10.1039/D1OB01353J>.
164. V. Rigolot, C. Biot, and C. Lion, "To View Your Biomolecule, Click Inside the Cell," *Angewandte Chemie International Edition* 60, no. 43 (2021): 23084–23105, <https://doi.org/10.1002/anie.202101502>.
165. S. H. L. Verhelst, K. M. Bongers, and L. I. Willems, "Bioorthogonal Reactions in Activity-Based Protein Profiling," *Molecules* 25, no. 24 (2020): 5994, <https://doi.org/10.3390/molecules25245994>.
166. Y. Hatanaka and M. Hashimoto, *Photoaffinity Labeling for Structural Probing Within Protein*, eds. Y. Hatanaka and M. Hashimoto (Springer Tokyo, 2017), <https://doi.org/10.1007/978-4-431-56569-7>.
167. A. H. Newman and S. Kulkarni, "Probes for the Dopamine Transporter: New Leads Toward a Cocaine-Abuse Therapeutic—A Focus on Analogues of Benztropine and Rimcazole," *Medicinal Research Reviews* 22, no. 5 (2002): 429–464, <https://doi.org/10.1002/med.10014>.
168. K. Wimalasena, "Vesicular Monoamine Transporters: Structure-Function, Pharmacology, and Medicinal Chemistry," *Medicinal Research Reviews* 31, no. 4 (2011): 483–519, <https://doi.org/10.1002/med.20187>.
169. S.-H. Yu, A. M. Wands, and J. J. Kohler, "Photoaffinity Probes for Studying Carbohydrate Biology," *Journal of Carbohydrate Chemistry* 31, no. 4–6 (2012): 325–352, <https://doi.org/10.1080/07328303.2012.676118>.
170. G. D. Holman, "Chemical Biology Probes of Mammalian GLUT Structure and Function," *Biochemical Journal* 475, no. 22 (2018): 3511–3534, <https://doi.org/10.1042/BCJ20170677>.
171. M. Hashimoto and Y. Hatanaka, "Recent Progress in Diazirine-Based Photoaffinity Labeling," *European Journal of Organic Chemistry* 2008, no. 15 (2008): 2513–2523, <https://doi.org/10.1002/ejoc.200701069>.
172. D. J. Lapinsky, S. Aggarwal, T. L. Nolan, et al., "(±)-2-(N-Tert-Butylamino)-3'-[¹²⁵I]-Iodo-4'-Azidopropiophenone: A Dopamine Transporter and Nicotinic Acetylcholine Receptor Photoaffinity Ligand Based on Bupropion (Wellbutrin, Zyban)," *Bioorganic & Medicinal Chemistry Letters* 22, no. 1 (2012): 523–526, <https://doi.org/10.1016/j.bmcl.2011.10.086>.
173. S. Puri and K. Juvele, "Monocarboxylate Transporter 1 and 4 Inhibitors as Potential Therapeutics for Treating Solid Tumours: A Review With Structure-Activity Relationship Insights," *European Journal of Medicinal Chemistry* 199 (2020): 112393, <https://doi.org/10.1016/j.ejmech.2020.112393>.
174. J. K. Buolamwini, J. D. Craik, J. S. Wiley, et al., "Conjugates of Fluorescein and SAENTA (5'-S-(2-Aminoethyl)-N⁶-(4-Nitrobenzyl)-5'-Thioadenosine): Flow Cytometry Probes for the Es Nucleoside Transporter Elements of the Plasma Membrane," *Nucleosides and Nucleotides* 13, no. 1–3 (1994): 737–751, <https://doi.org/10.1080/15257779408013276>.
175. M. T. Vanier, "Niemann-Pick Disease Type C," *Orphanet Journal of Rare Diseases* 5, no. 1 (2010): 16, <https://doi.org/10.1186/1750-1172-5-16>.
176. R. H. Kramer and J. W. Karpen, "Spanning Binding Sites on Allosteric Proteins With Polymer-Linked Ligand Dimers," *Nature* 395, no. 6703 (1998): 710–713, <https://doi.org/10.1038/27227>.
177. L. Tian and T. Heyduk, "Bivalent Ligands With Long Nanometer-Scale Flexible Linkers," *Biochemistry* 48, no. 2 (2009): 264–275, <https://doi.org/10.1021/bi801630b>.
178. M. Schapira, M. F. Calabrese, A. N. Bullock, and C. M. Crews, "Targeted Protein Degradation: Expanding the Toolbox," *Nature Reviews Drug Discovery* 18, no. 12 (2019): 949–963, <https://doi.org/10.1038/s41573-019-0047-y>.
179. A. A. Antolin, D. Sanfelice, A. Crisp, et al., "The Chemical Probes Portal: An Expert Review-Based Public Resource to Empower Chemical Probe Assessment, Selection and Use," *Nucleic Acids Research* 51, no. D1 (2023): D1492–D1502, <https://doi.org/10.1093/nar/gkac909>.
180. M. Mammen, S.-K. Choi, and G. M. Whitesides, "Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors," *Angewandte Chemie International Edition* 37, no. 20 (1998): 2754–2794, [https://doi.org/10.1002/\(SICI\)1521-3773\(19981102\)37:20<2754::AID-ANIE2754>3.0.CO;2-3](https://doi.org/10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3).
181. J. R. Lane, P. M. Sexton, and A. Christopoulos, "Bridging the Gap: Bitopic Ligands of G-Protein-Coupled Receptors," *Trends in Pharmacological Sciences* 34, no. 1 (2013): 59–66, <https://doi.org/10.1016/j.tips.2012.10.003>.
182. P. S. Portoghese, "Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists," *Trends in Pharmacological Sciences* 10, no. 6 (1989): 230–235, [https://doi.org/10.1016/0165-6147\(89\)90267-8](https://doi.org/10.1016/0165-6147(89)90267-8).
183. C. Hiller, J. Kühhorn, and P. Gmeiner, "Class A G-Protein-Coupled Receptor (GPCR) Dimers and Bivalent Ligands," *Journal of Medicinal Chemistry* 56, no. 17 (2013): 6542–6559, <https://doi.org/10.1021/jm4004335>.
184. F. Shen and L. M. K. Dassama, "Opportunities and Challenges of Protein-Based Targeted Protein Degradation," *Chemical Science* 14, no. 32 (2023): 8433–8447, <https://doi.org/10.1039/D3SC02361C>.
185. A. C. Lai and C. M. Crews, "Induced Protein Degradation: An Emerging Drug Discovery Paradigm," *Nature Reviews Drug Discovery* 16, no. 2 (2017): 101–114, <https://doi.org/10.1038/nrd.2016.211>.
186. M. Toure and C. M. Crews, "Small-Molecule PROTACS: New Approaches to Protein Degradation," *Angewandte Chemie International Edition* 55, no. 6 (2016): 1966–1973, <https://doi.org/10.1002/anie.201507978>.
187. M. Békés, D. R. Langley, and C. M. Crews, "PROTAC Targeted Protein Degradation: The Past Is Prologue," *Nature Reviews Drug Discovery* 21, no. 3 (2022): 181–200, <https://doi.org/10.1038/s41573-021-00371-6>.
188. M. Guharoy, P. Bhowmick, M. Sallam, and P. Tompa, "Tripartite Degrons Confer Diversity and Specificity on Regulated Protein Degradation in the Ubiquitin-Proteasome System," *Nature Communications* 7, no. 1 (2016): 10239, <https://doi.org/10.1038/ncomms10239>.
189. C. Davis, B. L. Spaller, and A. Matouschek, "Mechanisms of Substrate Recognition by the 26S Proteasome," *Current Opinion in Structural Biology* 67 (2021): 161–169, <https://doi.org/10.1016/j.sbi.2020.10.010>.

190. H. Gao, X. Sun, and Y. Rao, "PROTAC Technology: Opportunities and Challenges," *ACS Medicinal Chemistry Letters* 11, no. 3 (2020): 237–240, <https://doi.org/10.1021/acsmchemlett.9b00597>.
191. M. Pettersson and C. M. Crews, "Proteolysis Targeting Chimeras (PROTACs)—Past, Present and Future," *Drug Discovery Today: Technologies* 31 (2019): 15–27, <https://doi.org/10.1016/j.ddtec.2019.01.002>.
192. M. Decker and J. Lehmann, "Agonistic and Antagonistic Bivalent Ligands for Serotonin and Dopamine Receptors Including Their Transporters," *Current Topics in Medicinal Chemistry* 7, no. 4 (2007): 347–353, <https://doi.org/10.2174/156802607779941297>.
193. A. P. Tamiz, P. Conti, M. Zhang, K. M. Johnson, and A. P. Kozikowski, "A Convenient Procedure for the Synthesis of Nonsymmetrical Bivalent Selective Serotonin Reuptake Inhibitors Using Polymer-Supported Reagents," *Bioorganic & Medicinal Chemistry Letters* 10, no. 24 (2000): 2741–2743, [https://doi.org/10.1016/S0960-894X\(00\)00576-X](https://doi.org/10.1016/S0960-894X(00)00576-X).
194. A. P. Tamiz, J. Zhang, M. Zhang, C. Z. Wang, K. M. Johnson, and A. P. Kozikowski, "Application of the Bivalent Ligand Approach to the Design of Novel Dimeric Serotonin Reuptake Inhibitors," *Journal of the American Chemical Society* 122, no. 22 (2000): 5393–5394, <https://doi.org/10.1021/ja000199f>.
195. K. Fandrick, X. Feng, A. Janowsky, R. Johnson, and J. R. Cashman, "Bivalent Biogenic Amine Reuptake Inhibitors," *Bioorganic & Medicinal Chemistry Letters* 13, no. 13 (2003): 2151–2154, [https://doi.org/10.1016/S0960-894X\(03\)00386-X](https://doi.org/10.1016/S0960-894X(03)00386-X).
196. A. P. Tamiz, B. C. Bandyopadhyay, J. Zhang, et al., "Pharmacological and Behavioral Analysis of the Effects of Some Bivalent Ligand-Based Monoamine Reuptake Inhibitors," *Journal of Medicinal Chemistry* 44, no. 10 (2001): 1615–1622, <https://doi.org/10.1021/jm000552s>.
197. A. Brinkø, M. T. Larsen, H. Koldsø, et al., "Synthesis and Inhibitory Evaluation of 3-Linked Imipramines for the Exploration of the S2 Site of the Human Serotonin Transporter," *Bioorganic & Medicinal Chemistry* 24, no. 12 (2016): 2725–2738, <https://doi.org/10.1016/j.bmc.2016.04.039>.
198. P. Plenge, L. Shi, T. Beuming, et al., "Steric Hindrance Mutagenesis in the Conserved Extracellular Vestibule Impedes Allosteric Binding of Antidepressants to the Serotonin Transporter," *Journal of Biological Chemistry* 287, no. 47 (2012): 39316–39326, <https://doi.org/10.1074/jbc.M112.371765>.
199. Z. Zhou, J. Zhen, N. K. Karpowich, et al., "LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake," *Science* 317, no. 5843 (2007): 1390–1393, <https://doi.org/10.1126/science.1147614>.
200. S. K. Singh, A. Yamashita, and E. Gouaux, "Antidepressant Binding Site in a Bacterial Homologue of Neurotransmitter Transporters," *Nature* 448, no. 7156 (2007): 952–956, <https://doi.org/10.1038/nature06038>.
201. P. Zhang, G. Cyriac, T. Kopajtic, et al., "Structure–Activity Relationships for a Novel Series of Citalopram (1-(3-(Dimethylamino)Propyl)-1-(4-Fluorophenyl)-1,3-Dihydroisobenzofuran-5-Carbonitrile) Analogues at Monoamine Transporters," *Journal of Medicinal Chemistry* 53, no. 16 (2010): 6112–6121, <https://doi.org/10.1021/jm1005034>.
202. S. Sinning, M. Musgaard, M. Jensen, et al., "Binding and Orientation of Tricyclic Antidepressants Within the Central Substrate Site of the Human Serotonin Transporter," *Journal of Biological Chemistry* 285, no. 11 (2010): 8363–8374, <https://doi.org/10.1074/jbc.M109.045401>.
203. J. Andersen, L. Olsen, K. B. Hansen, et al., "Mutational Mapping and Modeling of the Binding Site for (S)-Citalopram in the Human Serotonin Transporter," *Journal of Biological Chemistry* 285, no. 3 (2010): 2051–2063, <https://doi.org/10.1074/jbc.M109.072587>.
204. S. Sarker, R. Weissensteiner, I. Steiner, et al., "The High-Affinity Binding Site for Tricyclic Antidepressants Resides in the Outer Vestibule of the Serotonin Transporter," *Molecular Pharmacology* 78, no. 6 (2010): 1026–1035, <https://doi.org/10.1124/mol.110.067538>.
205. F. Chen, M. B. Larsen, C. Sánchez, and O. Wiborg, "The S-Enantiomer of R,S-Citalopram, Increases Inhibitor Binding to the Human Serotonin Transporter by an Allosteric Mechanism. Comparison With Other Serotonin Transporter Inhibitors," *European Neuropsychopharmacology* 15, no. 2 (2005): 193–198, <https://doi.org/10.1016/j.euroneuro.2004.08.008>.
206. D. Chirnomas, K. R. Hornberger, and C. M. Crews, "Protein Degradation Enters the Clinic—a New Approach to Cancer Therapy," *Nature Reviews Clinical Oncology* 20, no. 4 (2023): 265–278, <https://doi.org/10.1038/s41571-023-00736-3>.
207. W. A. Velema, W. Szymanski, and B. L. Feringa, "Photopharmacology: Beyond Proof of Principle," *Journal of the American Chemical Society* 136, no. 6 (2014): 2178–2191, <https://doi.org/10.1021/ja413063e>.
208. N. Ankenbruck, T. Courtney, Y. Naro, and A. Deiters, "Optochemical Control of Biological Processes in Cells and Animals," *Angewandte Chemie International Edition* 57, no. 11 (2018): 2768–2798, <https://doi.org/10.1002/anie.201700171>.
209. P. Klán, T. Šolomek, C. G. Bochet, et al., "Photoremovable Protecting Groups in Chemistry and Biology: Reaction Mechanisms and Efficacy," *Chemical Reviews* 113, no. 1 (2013): 119–191, <https://doi.org/10.1021/cr300177k>.
210. A. Deiters, "Principles and Applications of the Photochemical Control of Cellular Processes," *ChemBioChem* 11, no. 1 (2010): 47–53, <https://doi.org/10.1002/cbic.200900529>.
211. M. Irie and K. Uchida, "Synthesis and Properties of Photochromic Diarylethenes With Heterocyclic Aryl Groups," *Bulletin of the Chemical Society of Japan* 71, no. 5 (1998): 985–996, <https://doi.org/10.1246/bcsj.71.985>.
212. A. A. Beharry and G. A. Woolley, "Azobenzene Photoswitches for Biomolecules," *Chemical Society Reviews* 40, no. 8 (2011): 4422–4437, <https://doi.org/10.1039/c1cs15023e>.
213. H. M. D. Bandara and S. C. Burdette, "Photoisomerization in Different Classes of Azobenzene," *Chemical Society Reviews* 41, no. 5 (2012): 1809–1825, <https://doi.org/10.1039/C1CS15179G>.
214. M. Ricart-Ortega, J. Font, and A. Llebaria, "GPCR Photopharmacology," *Molecular and Cellular Endocrinology* 488 (2019): 36–51, <https://doi.org/10.1016/j.mce.2019.03.003>.
215. P. D. Bregestovski and G. V. Maleeva, "Photopharmacology: A Brief Review Using the Control of Potassium Channels as an Example," *Neuroscience and Behavioral Physiology* 49, no. 2 (2019): 184–191, <https://doi.org/10.1007/s11055-019-00713-3>.
216. O. Sadvovskii, A. A. Beharry, F. Zhang, and G. A. Woolley, "Spectral Tuning of Azobenzene Photoswitches for Biological Applications," *Angewandte Chemie International Edition* 48, no. 8 (2009): 1484–1486, <https://doi.org/10.1002/anie.200805013>.
217. C. Brown, S. K. Rastogi, S. L. Barrett, et al., "Differential Azobenzene Solubility Increases Equilibrium Cis/Trans Ratio in Water," *Journal of Photochemistry and Photobiology, A: Chemistry* 336 (2017): 140–145, <https://doi.org/10.1016/j.jphotochem.2016.12.013>.
218. K. Shimamoto, R. Sakai, K. Takaoka, et al., "Characterization of Novel L-Threo-β-Benzyloxyaspartate Derivatives, Potent Blockers of the Glutamate Transporters," *Molecular Pharmacology* 65, no. 4 (2004): 1008–1015, <https://doi.org/10.1124/mol.65.4.1008>.
219. V. Eulenburg, W. Armsen, H. Betz, and J. Gomeza, "Glycine Transporters: Essential Regulators of Neurotransmission," *Trends in Biochemical Sciences* 30, no. 6 (2005): 325–333, <https://doi.org/10.1016/j.tibs.2005.04.004>.
220. R. J. Vandenberg, R. M. Ryan, J. E. Carland, W. L. Imlach, and M. J. Christie, "Glycine Transport Inhibitors for the Treatment of Pain," *Trends in Pharmacological Sciences* 35, no. 8 (2014): 423–430, <https://doi.org/10.1016/j.tips.2014.05.006>.
221. A. Mingorance-Le Meur, P. Ghisdal, B. Mullier, et al., "Reversible Inhibition of the Glycine Transporter GlyT2 Circumvents Acute Toxicity While Preserving Efficacy in the Treatment of Pain," *British*

Journal of Pharmacology 170, no. 5 (2013): 1053–1063, <https://doi.org/10.1111/bph.12343>.

222. M. Wijnmans, I. Josimovic, H. F. Vischer, and R. Leurs, “Optical Control of Class A G Protein-Coupled Receptors With Photoswitchable Ligands,” *Current Opinion in Pharmacology* 63 (2022): 102192, <https://doi.org/10.1016/j.coph.2022.102192>.

223. E. Smorodina, I. Diankin, F. Tao, R. Qing, S. Yang, and S. Zhang, “Structural Informatic Study of Determined and AlphaFold2 Predicted Molecular Structures of 13 Human Solute Carrier Transporters and Their Water-Soluble QTY Variants,” *Scientific Reports* 12, no. 1 (2022): 20103, <https://doi.org/10.1038/s41598-022-23764-y>.